Final Program

Transcription

Final Program

33rd Annual Meeting
International Society for
Pediatric and Adolescent Diabetes
Final Program
September 26 – 29, 2007
Berlin, Germany
Diabetes In Motion
In The Year Of The Child
www.ispad2007.com
4H
HERE
EISA
AREA
ALD
DIFFE
EREN
NCEB
BETWEEN
NB
BASALnB
BOLLUSTTHE
ERA
APIE
ESFFORCCHIILDRRENx
p

.OVO2APID &LEX0EN 5ML SOLUTION FOR
INJECTION IN A PRElLLED PEN .OVO2APID 0ENlLL
5ML SOLUTION FOR INJECTION IN A CARTRIDGE
.OVO2APID 5ML SOLUTION FOR INJECTION IN A
VIAL !CTIVE SUBSTANCE )NSULIN ASPART #OMPOSITION
!CTIVE PHARMACEUTICAL INGREDIENT 5ML INSULIN
ASPART GENETICALLY PRODUCED FROM RECOMBINANT $.!
%XCIPIENTS 'LYCEROL PHENOL METACRESOL ZINC CHLORIDE
SODIUM CHLORIDE DISODIUM PHOSPHATE DIHYDRATE
HYDROCHLORIC ACID ANDOR SODIUM HYDROXIDE WATER FOR
INJECTIONS4HERAPEUTICINDICATIONS$IABETESMELLITUS
-ETHOD OF ADMINISTRATION .OVO2APID 5ML
SOLUTION FOR INJECTION IN VIALS WITH INSULIN SYRINGES
ACCORDING TO THE APPROPRIATE DOSING SCALE .OVO2APID
0ENlLL 5ML SOLUTION FOR INJECTION IN A CARTRIDGE
WITH THE .OVO .ORDISK INSULIN INJECTION SYSTEM AND
.OVO&INE INJECTION NEEDLES .OVO2APID &LEX0EN
WITH .OVO&INE INJECTION NEEDLES MM IN LENGTH OR
SHORTER .OVO2APID CAN ALSO BE USED FOR CONTINUOUS
SUBCUTANEOUS INSULIN INFUSION #3)) IN PUMP SYSTEMS
WHICH ARE SUITABLE FOR INSULIN INFUSION )F NECESSARY
.OVO2APID CAN ALSO BE ADMINISTERED INTRAVENOUSLY
BUTONLYBYMEDICALPROFESSIONALS)NSULINASPARTCANBE
USED DURING PREGNANCY $OSE MAY NEED TO BE ADJUSTED
BYTHEDOCTORDURINGPREGNANCYORWHENBREASTFEEDING
ORIFAPREGNANCYISBEINGPLANNED#ONTRAINDICATIONS
(YPOGLYCAEMIAHYPERSENSITIVITYTOINSULINASPARTORANY
OFTHEEXCIPIENTS5NDESIRABLEEFFECTS(YPOGLYCAEMIA
VISUALDISTURBANCESOROEDEMAUPONINITIATIONOFTREATMENT
,OCAL HYPERSENSITIVITY REACTIONS AT THE INJECTION SITE
5NCOMMONLYURTICARIAEXANTHEMASKINRASHVERYRARELY
GENERALISEDHYPERSENSITIVITYREACTIONSWHICHMAYBELIFE
THREATENING,IPODYSTROPHYATTHEINJECTIONSITEIFINJECTED
TOOFREQUENTLYINTOTHESAMEPLACE4RANSIENTNEUROPATHY
OR WORSENING OF DIABETIC RETINOPATHY DURING ABRUPT
IMPROVEMENT IN GLYCAEMIC CONTROL 0RESCRIPTIONONLY
MEDICINE .OVO .ORDISK !3 .OVO !LLÏ $+
"AGSVRD$ENMARK4EXTLASTREVISED!UGUST
,EVEMIR 5ML SOLUTION FOR INJECTION IN A
CARTRIDGE 0ENlLL ,EVEMIR 5ML SOLUTION
FOR INJECTION IN A PRElLLED PEN &LEX0EN !CTIVE
SUBSTANCE )NSULIN DETEMIR #OMPOSITION !CTIVE
PHARMACEUTICAL INGREDIENT 5ML INSULIN DETEMIR
GENETICALLY PRODUCED FROM RECOMBINANT $.! IN
3ACCHAROMYCES CEREVISIAE %XCIPIENTS 'LYCEROL PHENOL
METACRESOLZINCACETATEDISODIUMPHOSPHATEDIHYDRATE
SODIUM CHLORIDE HYDROCHLORIC ACID SODIUM HYDROXIDE
WATERFORINJECTIONS4HERAPEUTICINDICATIONS$IABETES
MELLITUS-ETHODOFADMINISTRATION,EVEMIR5ML
SOLUTION FOR INJECTION HAS BEEN DEVELOPED FOR USE WITH
THE.OVO.ORDISKINSULININJECTIONSYSTEMSAND.OVO&INE
INJECTIONNEEDLES.OVO&INEINJECTIONNEEDLESMMIN
LENGTH OR SHORTER ARE PROVIDED FOR USE WITH ,EVEMIR
IN THE &LEX0EN #ONTRAINDICATIONS (YPOGLYCAEMIA
HYPERSENSITIVITY TO INSULIN DETEMIR OR ANY OF THE
EXCIPIENTS .O DATA IS AVAILABLE ON THE CLINICAL USE OF
INSULINDETEMIRDURINGPREGNANCYORWHENBREASTFEEDING
#AUTION IS RECOMMENDED WHEN USING THIS PRODUCT
DURINGPREGNANCYORWHENBREASTFEEDING5NDESIRABLE
EFFECTS(YPOGLYCAEMIAVISUALDISTURBANCESOROEDEMA
UPON INITIATION OF TREATMENT 2EACTIONS AT THE INJECTION
SITE REDNESS SWELLING INmAMMATION ITCHING AND
BRUISING ,IPODYSTROPHY AT THE INJECTION SITE IF INJECTED
TOO FREQUENTLY INTO THE SAME PLACE !LLERGIC REACTIONS
POTENTIALLY ALLERGIC REACTIONS URTICARIA AND RASHES VERY
RARELYGENERALISEDHYPERSENSITIVITYREACTIONSWHICHMAY
BE LIFETHREATENING 2ARELY NEUROPATHY IN THE ARMS AND
LEGSDURINGFASTIMPROVEMENTOFBLOODGLUCOSECONTROL
0RESCRIPTIONONLY MEDICINE .OVO .ORDISK !3
.OVO !LLÏ $+ "AGSVRD $ENMARK 4EXT LAST
REVISED*UNE
2EFERENCES
2OBERTSON + ET AL )NSULIN DETEMIR COMPARED WITH
.0( INSULIN IN CHILDREN AND ADOLESCENTS WITH TYPE DIABETES$IABETES -ED n $ANNE 4
ET AL ! COMPARISON OF POSTPRANDIAL AND PREPRANDIAL
ADMINISTRATION OF INSULIN ASPART IN CHILDREN AND
ADOLESCENTSWITHTYPEDIABETES$IABETES#ARE
n)-3(EALTH7ORLDWIDE3ALES$ATA-AY
,EVEMIR 3UMMARY OF 0RODUCT #HARACTERISTICS
.OVO2APID3UMMARYOF0RODUCT#HARACTERISTICS
,EVEMIR.OVO2APID
%FFECTIVEGLYCAEMICCONTROL
3IGNIlCANTREDUCTIONOFNOCTURNAL
HYPOGLYCAEMIACOMPAREDTOHUMANINSULIN
,ESSUNDESIRABLEWEIGHTGAIN
&LEXIBILITYAROUNDMEALTIMES
!VAILABLEIN&LEX0ENTRUSTEDBYMILLIONS
OFPEOPLEEVERYDAY
,EVEMIR .OVO2APID &LEX0EN0ENFILL AND.OVO&INE
AREREGISTEREDTRADEMARKSOF.OVO.ORDISK! 3
p4HEEFFICACYANDSAFETYOF,EVEMIR WEREDEMONSTRATED
INCHILDRENANDADOLESCENTSAGEDTOYEARSINSTUDIES
UPTOMONTHS .OVO2APID CANBEUSEDINCHILDRENINPREFERENCE
TOSOLUBLEHUMANINSULINWHENARAPIDONSETOFACTION
MIGHTBEBENEFICIAL.OSTUDIESHAVEBEENPERFORMED
INCHILDRENUNDERTHEAGEOFYEARS )-3(EALTH7ORLDWIDE3ALES$ATA
o#OMPAREDTO.0(INSULIN
$ATEOFPREPARATION!UGUST
o
September 26 – 29, 2007 | Berlin
Table of Contents
Table of Contents
Table of Contents
3
The Conference Venue
40
Welcome Messages
4
Floor Plans
41
About ISPAD
8
Exhibition Map
42
Key Facts / Committees
9
Getting There and Away
44
General Conference Information
10
Public Transportation Map
45
Program Overview
14
Hotel Contact Information
46
Program for Wednesday, September 26
16
The City of Berlin
48
Program for Thursday, September 27
20
Berlin City & Hotel Map
49
Program for Friday, September 28
23
Social Program
50
Program for Saturday, September 29
29
Tours
52
Poster Sessions
32
ISPAD Membership Application Form
54
Sponsors
ISPAD 2007 would like to thank the following sponsors.
Platinum
Gold
Silver
www.ispad2007.com
3
33rd Annual Meeting | International Society for Pediatric and Adolescent Diabetes
Welcome Message
Welcome Message by the Conference President
Olga Kordonouri
Dear Colleagues and Friends,
It is a great pleasure to welcome you all to the 33rd Annual Meeting of the International Society
for Pediatric and Adolescent Diabetes here in Berlin.
During the conference, you will have the opportunity to network with your colleagues and
friends from all over the world and to learn about the latest developments in basic research
and clinical best practice.
Only a few months ago, the United Nations General Assembly has passed a landmark
resolution recognizing the global threat of the diabetes epidemic. For the first time,
governments have acknowledged that a non-infectious disease is a serious global threat
as the infectious epidemics. Passing the UN Resolution, while monumental for the diabetes
world, is just the first step. ISPAD is the only international society focusing specifically on
all types of childhood diabetes. Thus, the slogan of our meeting is “Diabetes in Motion in the
Year of the Child” indicating the rapidly changing field of pediatric diabetology. People need
to understand that diabetes is different in children. This field is gaining momentum with more
and more youth affected worldwide. On the other hand, new insights in the pathogenesis,
diagnosis and treatment of different diabetes forms in children lead to quickly changing
approaches to science and care everywhere. This ISPAD meeting promises to give you
a comprehensive overview of the fast-moving field of pediatric diabetes all over the world.
Olga Kordonouri
Conference President
The special multicultural atmosphere of Berlin, Germany’s rapidly transforming capital at the
cultural and financial intersection between East and West, will provide a perfect background
both to experience scientific achievements and to create new collaborations and friendships.
The city is the symbol of Germany’s reunification, pulsing centre of culture and magnet for
artists, students and young people from all over the world.
On behalf of the Organizing Committee
Yours sincerely,
4
www.ispad2007.com
Welcome Message
Welcome Message from the Federal Minister of
Family Affairs, Senior Citizens, Women and Youth
Ursula Gertrud von der Leyen
Throughout the last century, we have witnessed improvements in the health situation of
children and young people in the industrialised countries of a magnitude that was previously
unthinkable in human history. The achievements in medicine and progress in hygiene and
sanitation – the decrease in infant and child mortality, high life expectancy and the treatment
of infectious diseases with the aid of effective medicines – have already become perfectly
normal for our generation.
This notwithstanding, all of these medical achievements, from which our children profit
nowadays, should not blind us to the fact that serious health problems – which affect a
substantial segment of the population – still exist today. Over 20 percent of today’s parents
have a chronically sick child to care for; some ten percent of our children under the age of 15
suffer from asthma; one child out of five in Germany is overweight and the trend towards
overweight and lack of exercise among children is still on the rise. Annually, approximately
200 children between the ages of 12 and 19 years develop Type 2 diabetes. This trend, too,
is a growing one.
Ursula Gertrud von der Leyen
Federal Minister of
Family Affairs, Senior Citizens,
Women and Youth
Policy-makers, the medical profession and society are jointly and equally challenged at this
juncture. Nowadays, a healthy diet, sufficient exercise and early promotion are part of every
child’s basic needs. It is imperative that we create proper conditions in our homes, nursery
school settings, with day-care mothers and in schools, so that our children can grow up in
a healthy environment.
A good start in life is decisive. This applies especially to the opportunities to which children
with a migrant background have access early in life. Today, already one out of three children
under the age of six comes from a migrant background. The most recent figures reveal that
precisely these families do not avail themselves of the existing early detection opportunities.
This is why I find it so important for greater prominence to be given to the topic of health
in nursery schools, schools and family education centres. We need to approach children and
parents and make low-threshold opportunities available to them in those places where they
are easily accessed and where they spend time every day.
Here in Berlin, we have a great role model in the person of the doctor and politician, Rudolf
Virchow. As early as the beginning of the previous century, he showed how broad-based
commitment was able to achieve improved health for all. Today, we are all being challenged
to work together to ensure our children’s health. I wish you, the participants of this Annual
Congress of the International Society of Pediatric and Adolescent Diabetes many good
statements and contributions, new inspiration and ideas and the greatest possible success
for your event.
www.ispad2007.com
5
Welcome Message
Welcome Message from the Governing Mayor of Berlin
Klaus Wowereit
I would like to welcome all the participants to the Annual Meeting of the International Society for
Pediatric and Adolescent Diabetes, ISPAD, to Berlin. It is both an honor and a pleasure for us to have
you hold this important scientific congress here in Germany’s capital city. I also see this choice as
an acknowledgement of the excellent conditions our city has to offer.
Berlin is an international congress venue offering its guests the perfect environment for intensive
exchange among experts. We are particularly proud that our city has become one of the leading
venues for congresses focusing on medicine and health-related issues. The fact that the
International Society for Pediatric and Adolescent Diabetes is holding its Annual Meeting here
illustrates the fine reputation the city has acquired in this field.
Klaus Wowereit
Governing Mayor of Berlin
Apart from that, Berlin is also very highly regarded as a city of science and medicine. More than
100 years ago, Berlin already had a very varied scientific landscape. It was one of the cities where
global standards were set, not only in medicine but also in chemistry and physical science.
Four scientists based in Berlin won a Nobel prize for medicine at the beginning of the last century.
This long-standing tradition is now helping Berlin to sharpen its profile as a modern health-care
center of excellence. With our well-known hospitals, like the prestigious Charité, our highly
acclaimed medical schools, our numerous research institutions and international top-class
achievements in medical technology, biomedicine, and genome research, we are already well
prepared for the future.
With all this in mind, I would once again like to welcome all of the participants to the 33rd Annual
Meeting of the International Society for Pediatric und Adolescent Diabetes to Berlin. I wish you
a successful and inspiring congress, and I hope that you will also have some time to explore our
exciting metropolis. Unique cultural attractions and a trendy scene are waiting for you.
Welcome to Berlin!
6
www.ispad2007.com
Welcome Message
Presidential Words of Wisdom
Stuart Brink
As the President of ISPAD and on behalf of the ISPAD Steering Committee, Advisory Council
and membership, we would like to welcome you to our Annual Scientific Meeting. ISPAD has
grown to be the premier pediatric and adolescent diabetes society in the world. Our members
are active clinicians as well as researchers and educators.
We participate in efforts to improve care, psychosocial function and reduce the acute as well
as chronic complications of diabetes. Our meetings are scientifically rigorous, provocative,
cutting edge and interactive. Such meetings continue to serve as a focus for collegial
interchange, promoting collaborative teaching as well as research efforts and as a means to
bring together those interested in pediatric and adolescent diabetes wherever they may be.
Stuart Brink
President of ISPAD
We also provide a means for collaborative efforts with the pharmaceutical and other diabetes
support industries not only to meet with our members but also to assist in ISPAD endeavors
such as ISPAD science schools, research training programs offered by our members and the
special ISPAD awards.
The three key ISPAD awards, the ISPAD Prize for Scientific Achievement, the ISPAD Lestradet
Award for Education and Advocacy and the ISPAD Young Investigator Award are presented
each year and this will continue in Berlin to honor superb efforts by our members.
The ISPAD Annual Business Meeting will take place in Berlin during the Annual Scientific
Meeting and will provide an opportunity to vote for new officials of ISPAD as well as to hear
about the international collaborative postgraduate programs organized by ISPAD, cooperative
efforts with other endocrine and diabetes organizations and new initiatives.
www.ispad2007.com
7
About ISPAD
About ISPAD
ISPAD Prizes
ISPAD is a professional organization whose aims are to promote
clinical and basic science, education and advocacy in childhood
and adolescent diabetes. The strength of ISPAD lies in the
scientific and clinical expertise in childhood and adolescent
diabetes of its members. ISPAD is the only international society
focusing specifically on all types of childhood diabetes.
ISPAD Best Oral / Poster Prize
ISPAD Steering Committee
Stuart Brink
Thomas Danne
Lynda K. Fisher
Denis Daneman
President
Secretary-General
Treasurer
Immediate Past-President
ISPAD Advisory Council
Carlo Acerini
Ethel Codner
Alan M. Delamater
Gun Forsander
Marcia Frank
Ragnar Hanas
Areti Philotheou
Joseph Wolfsdorf
Officer
Officer
Officer
Officer
Officer
Officer
Officer
Officer
ISPAD
International Society for Pediatric
and Adolescent Diabetes
Find out more about ISPAD at www.ispad.org!
8
The ISPAD Best Oral Prize and also the ISPAD Best Poster Prize
will be given to any individual (ISPAD Member and Non-Member)
who has submitted an abstract to the 33rd Annual Meeting of the
International Society for Pediatric and Adolescent Diabetes.
The papers will be judged and ranked by the Review Committee.
The best poster and oral presentation will be chosen at the
meeting by a prize committee under the auspices of the ISPAD
Steering Committee.
ISPAD Young Investigator Award –
Sponsored by Medtronic
Any ISPAD Member (aged 40 or less) could apply for the ISPAD
Young Investigator Award. The application had to include a
paper published in a peer reviewed journal within 2 years prior
to application. The award also includes a 15 minute presentation
during the “Young Investigator Lecture”.
ISPAD Lestradet Award for Education and Advocacy –
Sponsored by LifeScan
The ISPAD Lestradet Prize for Education and Advocacy
will be given to honor any nominee (ISPAD Member) who
has made an outstanding contribution within Education and
Advocacy. The beneficiary will hold a 30 minute talk during
the “Lestradet Lecture”.
ISPAD Prize for Achievement –
Sponsored by Eli Lilly & Company
The ISPAD Prize for Achievement is the society’s highest
honor. It is awarded to any individual who has made
outstanding contributions in the areas of Science, Education
or Advocacy which have had a major impact on childhood
and adolescent diabetes.
www.ispad2007.com
Key Facts / Committees
Committees
Contacts
Local Organizing Committee
Conference President
Bärbel Aschemeier, MPH, Hannover
Walter Burger, MD, Berlin
Dorothee Deiss, MD, Berlin
Holger Haberland, MD, Berlin
Mathias Herr, MD, Berlin
Wieland Kiess, MD, Leipzig
Karin Lange, PhD, Hannover
Renate Lauterborn, CDE, Berlin
Olga Kordonouri, MD
Kinderkrankenhaus auf der Bult
Janusz-Korczak-Allee 12
30173 Hannover, Germany
Tel.: +49-511-8115-349
Fax: +49-511-8115-344
kordonouri@hka.de
www.hka.de
Abstract Review Committee
Conference Secretariat
Carlo Acerini, MD, UK
Stuart Brink, MD, USA
Walter Burger, MD, Germany
Ondrej Cinek, MD, Czech Republic
Ethel Codner, MD, Chile
Gun Forsander, MD, Sweden
Wieland Kiess, MD, Germany
Olga Kordonouri, MD, Germany
Karin Lange, PhD, Germany
Areti Philoteou, MD, South Africa
Kubendran Pillay, MD, South Africa
Tatsuhiko Urakami, MD, Japan
Joseph Wolfsdorf, MD, USA
K.I.T. GmbH
Association & Conference Management Group & Co. KG
Kurfürstendamm 71
10709 Berlin, Germany
Tel.: +49-30-24603-0
Fax: +49-30-24603-200
ispad2007@kit-group.org
www.kit-group.org
Conference Venues
bcc Berliner Congress Center GmbH
Alexanderstrasse 11
www.bcc-berlin.de
Radisson SAS Hotel
(only Saturday, September 29, 2007)
Karl-Liebknecht-Str. 3
www.berlin.radissonsas.com
www.ispad2007.com
9
Abstract Book
The Abstract Book is published as a supplement to Pediatric
Diabetes. It will be distributed onsite to all participants. Online
access is also possible via www.blackwell-synergy.com.
Abstract CD
The Abstract CD, sponsored by Novo Nordisk, will be available
at the Novo Nordisk booth. Vouchers can be found in the
congress bags.
Accommodation
If you need to reserve a hotel room or if you have any problems
with your reservation, please visit the “Tours / Hotel” Desk in the
registration area.
How to get Credits
German Physicians will need to submit their barcode-stickers
issued by their Medical Chamber (Ärztekammer) for accreditation
purposes on each day for which they would like to receive CME
Credits. The barcode-stickers can only be handed in – after having
attended the morning and the afternoon sessions – at the CME
Counter, which is open every day during the last two hours of
the scientific program. Credits can only be awarded on a day-byday basis. It is not possible to apply for credits for activities in
advance or afterwards.
International Delegates can use the International Certificate of
Attendance as proof of their attendance and apply for credits
with their local authorities.
Cloakroom
Breakfast & Lunch Workshops
In addition to the official scientific program, Medtronic offers free
breakfast and lunch workshops on Thursday 27th and Friday 28th.
Advance Registration is required for these workshops. To learn
more, please check the detailed schedule in this Final Program or
visit the Medtronic booth.
A cloakroom is available at the conference center, open during
conference hours. Please note that luggage cannot be stored at
the cloakroom.
Coffee Breaks
Coffee and tea will be served free of charge to all registered
participants during the coffee breaks indicated in the program.
Certificate of Attendance
Please note that two Certificates of Attendance will be issued.
The International Certificate of Attendance can be found in the
congress bag. It is valid as general certificate of attendance and
can be used by international delegates to get CME credits from
their national authorities. The German Certificate of Attendance
will only be available on Friday afternoon at the CME Counter in
the bcc. The German Certificate of Attendance is only valid for
German authorities.
CME Credits
Ärztekammer Berlin
ISPAD 2007 has been accredited by the Ärztekammer Berlin for
a total of 21 CME credits, split as follows:
September 26: 6 credits | September 27: 6 credits
September 28: 6 credits | September 29: 3 credits
European Accreditation Council for Continuing Medical Education
ISPAD 2007 is accredited by the European Accreditation Council for
Continuing Medical Education (EACCME) to provide the following
CME activity for medical specialists. The EACCME is an institution of
the European Union of Medical Specialists, www.uems.net. ISPAD is
designated for a maximum of 21 hours of European external CME
credits. Each medical specialist should claim only those hours of
credit that he/she actually spent in educational activity. EACCME
credits are recognized by the American Medical Association
towards the Physician’s Records Award (PRA). To convert EACCME
credit to AMA PRA category 1 credits, contact the AMA.
10
Conference Bag
The Conference Bag, containing the conference material, can be
obtained at the Congress Bag Counter. Please make sure to have
the Congress Bag Voucher ready.
Currency
The national currency in Germany is the Euro (€). It is also the
standard currency for all payments in connection with ISPAD
2007. Credit cards (Visa / Mastercard / American Express / Diners
Club) are accepted as well. The nearest currency exchange office
and major banks can be found at the Alexanderplatz train station.
Exhibition
Conference participants are invited to visit the exhibition.
The exhibition will be open during the following times:
Wednesday, September 26, 2007
Thursday, September 27, 2007
Friday, September 28, 2007
08.00 – 18.30
08.00 – 15.30
08.00 – 17.00
Filming and Taking Pictures
Out of respect for author’s and speaker’s copyrights, it is
forbidden to take pictures and/or to film during any official
congress sessions. In case of negligence, the organizers reserve
the right to exclude the participant from the congress.
www.ispad2007.com
Insurance and Liability
Name Badge
The conference organizer, the International Society for Pediatric
and Adolescent Diabetes and the ISPAD Conference Secretariat
can not accept liability for personal injury, loss of or damage to
belongings of conference participants, either during or as a result
of the conference. Please check the validity of your
own insurance.
A badge is required for admittance to all official conference
sessions, the exhibition area, the opening ceremony, welcome
reception and social events. Each participant is asked to present
the badge in order to gain access to the conference. The name
badge must be worn and clearly displayed at all times. Access
to the conference facilities will not be granted without a proper
name badge.
Internet Café
The Internet Café, sponsored by Novo Nordisk, will be open to
all delegates during exhibition opening times and is located on
level C.
ISPAD Service Point
The Society will have a service point in the exhibition area
(Booth No. 6, level B) where members can ask questions,
pay their fees, get missing issues of Pediatric Diabetes, etc.
Non-Members are also invited to learn more about ISPAD.
Language
The official conference language is English. No simultaneous
translation will be provided.
Opening Ceremony & Welcome Reception
The Opening Ceremony on Wednesday, September 26, 2007
will take place from 18.30 to 19.30. It will be followed by a
Welcome Reception starting at 19.30. Both events are free
of charge to all registered delegates, accompanying persons
and industry representatives.
Opening Hours
Most shops and department stores are open Monday to Saturday
between 10.00 and 20.00. Larger shopping malls may be open
even longer, while smaller stores may also close at 18:00 or
earlier. With a few exceptions, all stores are closed on Sundays.
Poster Exhibition / Poster Sessions
Lost and Found
For lost items, please contact the bcc front office on level B
(Tel.: +49-30-23806-750).
Lost/ Forgotten Name Badge
In case you forget to bring your name badge/voucher letter to the
conference, a credit card guarantee for the total amount of the
registration fee will be required to get a replacement badge. In
addition, a non-refundable handling fee of € 30 will be charged.
Your old name badge will be de-activated and become invalid.
To release the credit card guarantee and avoid double payment,
the complete and undamaged original letter has to be sent to the
conference secretariat within four weeks after the conference.
If a delegate loses or misplaces his name badge, a handling
fee of € 30 will be charged for a new name badge. Your old name
badge will be de-activated and become invalid. Kindly note that
vouchers for the Social Program are not substitutable.
Lunches
Lunches will be available to all registered participants during
the lunch breaks indicated in the program.
Mobile Phones
Mobile phones must be set to silent mode in all session rooms at
all times.
www.ispad2007.com
The poster exhibition, sponsored by Bayer HealthCare Diabetes
Care, will be located in the room B08 – B09. The posters will
be present during the whole conference. Poster Sessions with
designated chairmen will take place at the times indicated in
the program. All poster presenters are asked to post their posters
well before this time and to be present during the times of
presentation. Material and the exact location of where to attach
the posters to the poster walls will be provided.
Press Conferences
Three official press conferences will be held during the congress:
ISPAD 2007 Press Conference
(supported by Novo Nordisk)
Tuesday, September 25, 11.00 – 12.00 – Westin Grand Hotel,
Salon Friedrichstadt
(supported by Eli Lilly & Company)
Thursday, September 27, 08.30 – 09.30 – berlin congress center,
room A01
(supported by Roche Diagnostics)
Thursday, September 27, 10.30 – 11.30 – berlin congress center,
room A01
11
Press Contact
Smoking Policy
Beate Schweizer
Press Office ISPAD 2007
P.O. Box 30 11 20
70451 Stuttgart
Tel.: +49-711-8931-295
Fax: +49-711-8931-167
schweizer@medizinkommunikation.org
There is a non-smoking policy throughout the conference venue.
Program Changes
The organizers cannot assume liability for any changes in the
program due to external or unforeseen circumstances. Please
check the website for regular updates. The organizers reserve the
right to cancel, postpone, relocate or change any of the sessions.
Speakers’ Center
Invited speakers, chairmen and oral abstract presenters must
report to the Speakers’ Center, located on Level B, room B04, at
least four hours prior to their presentation in order to check and
deposit their presentation. Please provide the data on a USB
Memory Stick or a CD-ROM. Please note that it is not allowed to
run the presentation from your personal laptop in the session
room. Video support is at the sole responsibility of the speaker.
The opening hours of the speakers’ center are the same as
registration opening hours.
Taxis
Public Transportation
The closest public transportation station is “Alexanderplatz”. It is
connected to S-Bahn (commuter trains), U-Bahn (subway), Trams
(streetcars) as well as regional railway traffic.
Please find a detailed map of the public transportation net on
page 45.
Participants with All-Inclusive-Registrations or BVG-TicketUpgrades may travel for free within the zones A+B (which cover
almost the whole city, including airports) between September 26
and September 30, 2007. Please note that your name badge will
be your official ticket for the public transportation; you will find
the following logo on your badge:
The nearest taxi stop is located at “Alexanderplatz”. Taxis are
indicated by the usual signs on the outside of the car.
Telephone
The country code for Germany is +49, the city code for Berlin
is 030. Mobile networks work with the GSM/UMTS standard at
900 and 1800 Mhz. Phone booths can be found at many public
places, but most of them work card-based. Cards can be bought
at newspaper stores.
Tipping
Prices are calculated to include taxes and services, but it is
customary to round up the bill. Gratuity is appreciated; it is
customary to leave a tip of 5% of the total sum of the bill in
restaurants and cafes.
26.– 30.09.07
Tourist Information
Registration
Delegates who have received pre-mailed badges do not need to
register on-site. They may directly proceed to the conference
areas and pick up their congress bags at any time with their
congress bag voucher.
Those without pre-mailed badges need to check in at the
appropriate registration desk. The registration desks are open
during the following times:
Tuesday, September 25
Wednesday, September 26
Thursday, September 27
Friday, September 28
Saturday, September 29
12
“Berlin Infostores” are located at the main train station, at the
Brandenburg Gate and at the Reichstag.
Tours
To book a tour or for questions about tours, please visit the
counter “Tours / Hotel” in the registration area.
Transfers
For transfers to and from Social Program locations, please check
the Social Program section for details (page 50 – 51).
15.00 – 18.00
07.00 – 18.30
07.00 – 15.30
07.00 – 17.00
07.00 – 12.00
www.ispad2007.com
Launching
in 2007
Df]aUfm7UfY8]UVYhYg
H\YcZZ]W]U`^cifbU`cZDf]aUfm7UfY8]UVYhYg9ifcdY"
9X]hcf!]b!7\]YZ.;imFihhYb
5ggcW]UhY9X]hcfg.?Ua`Yg\?\ibh] BY]Àibfc UbX
?AJYb_UhBUfUmUb
#
Df]aUfm 7UfY 8]UVYhYg diV`]g\Yg cf][]bU` fYgYUfW\
Ufh]W`Yg Vf]YZ fYdcfhg fYj]Ykg YX]hcf]U`g cd]b]cbg UbX
WUgY\]ghcf]YghcfYZ`YWhbYkW`]b]WU`fYgYUfW\UbXdfUWh]WY!
cf]YbhYXXYjY`cdaYbhg"
#
H\YdifdcgYcZh\Y^cifbU`]ghcYbWcifU[Y]bhYfX]gW]d`]bUfm
fYgYUfW\ UbX X]gWigg]cb cb Ub ]bhYfbUh]cbU` `YjY` UbX hc
fYZ`YWh h\Y gcW]Yhm¼g U]a cZ ]adfcj]b[ h\Y eiU`]hm cZ WUfY
Zcf dYcd`Y k]h\ X]UVYhYg aY``]hig k]h\]b h\Y df]aUfm!WUfY
gYhh]b["
#
Cb`]bY giVa]gg]cb UbX dYYf fYj]Yk Zcf gdYYXm cb`]bY
diV`]WUh]cbUh\hhd.##YYg"Y`gYj]Yf"Wca#dWX#
TOP 25 Hottest Articles
H\YHCD&)<chhYgh5fh]W`Yg]gUZfYYeiUfhYf`mgYfj]WYZfca
GW]YbWY8]fYWh" GiVgWf]VY hc h\Y HCD&) UbX fYWY]jY Ub
Y!aU]`YjYfmh\fYYacbh\g`]gh]b[h\YGW]YbWY8]fYWhigYfg¼
&)acghZfYeiYbh`mXckb`cUXYX^cifbUÙfh]W`Yg Zfcamcif
^cifbU`cZW\c]WY\hhd.##hcd&)"gW]YbWYX]fYWh"Wca#g][bid
:cfacfY]bZcfaUh]cbcf
hcgiVgWf]VYcb`]bY j]g]h.
]bh`"Y`gYj]Yf\YU`h\"Wca#^cifbU`g#dWX
Program Overview
Track I
Track II
Track I
Track II
Eli Lilly Breakfast Symposium:
Our Children with Diabetes:
Hearts at Risk
Medtronic Breakfast Workshops
07.00
08.00
09.00
DAWN Youth Breakfast
Symposium:
Changing the Future of
Childhood Diabetes:
New Insights, New Commitments
p. 16
Symposium:
New Kids on the Block:
Adipocytokines for Pediatric
Endocrinologists
Room C01
Break
10.00
Opening Session:
Diabetes in Motion in the Year
of the Child
p. 16
11.00
Room C01
p. 20
p. 20
Rooms A03/A04/A05/A06
Break
Room C01
p. 21
EURODIAB@ISPAD Symposium:
Recent Trends in Epidemiology
p. 21
Room B05 – B07
Coffee Break
Room C01
Plenary Session I:
Cells & Drugs:
New Approaches to Treatment
IDF@ISPAD Symposium:
DKA Prevention at Onset:
How to Achieve the Goal?
ESPE@ISPAD Symposium:
Diabetes & Puberty:
Mechanistic Views
12.00
p. 17
Room C01
Room C01
p. 21
Lunch Break
Lunch Break
Poster Session I
Plenary Session III:
incl. Lestradet Lecture
Educating the Educators:
Key Factors for Successful Programs
p. 22
Room B05 – B07
Medtronic Lunch Workshops
13.00
p. 22
14.00
Room B08 – B09
p. 17, 32 – 35
15.00
Plenary Session II:
Genes & Environment:
New Approaches to Prevention
p. 17
16.00
Coffee Break
17.00
Oral Presentation I:
Diabetes Care, Education,
Psychosocial Issues
18.00
Break
p. 17
Room C01
p. 22
Social Afternoon
Boat Trip & Garden Party
Room C01
Oral Presentation II:
Immunology and Genetics
of Diabetes
Room C01
p. 18
Room B05 – B07
Opening Ceremony
19.00
p. 20, 50
Room C01
Welcome Reception
20.00
p. 20, 50
Level B / C
p. 23, 50 – 51
Haus der Kulturen der Welt
21.00
14
www.ispad2007.com
Program Overview
Saturday,
September 29
Track I
Track II
Track III
Track I *
Roche Breakfast Symposium:
Contributors to a Good Diabetes
Management for the Young
Terumo Breakfast Symposium:
Decreasing Pain in Children
with Diabetes
p. 23
p. 23
p. 29
07.00
08.00
09.00
Room C01
Break
Plenary Session IV:
Great Beginnings: Neonatal
Origins of Later Diabetes
Plenary Session V:
5th Symposium on Diabetic
Angiopathy in Children
Glycemic Targets to Prevent
Complications in Children
10.00
p. 24
Room C01
p. 29
Oral Presentation III:
Diabetes Acute and
Chronic Complications
Oral Presentation IV:
Beta Cell and Adipocyte Function,
New Insulins
12.00
p. 24
Room Saphir
Coffee Break
Coffee Break
11.00
Room Saphir
Break
Room C01
p. 25
Room B05 – B07
Lunch
Symposium:
Politics and Pediatric Diabetes:
How to Ensure Equal Standards
of Care – The European Example
p. 26
Room A01
Plenary Session VI:
5th Symposium on Diabetic
Angiopathy in Children
Early Recognition and Early
Treatment of Late Complications
in Children – Where Are We Now?
p. 29
13.00
p. 27
Room Saphir
Closing Session
p. 30
Room Saphir
Farewell Lunch
Poster Session II
14.00
p. 27, 32, 36 – 39
Room B08 – B09
15.00
Symposium:
Update on the ISPAD Clinical
Practice Consensus Guidelines
2006/2007
Workshop I:
Is Carbohydrate Counting Essential
for Successful Treatment?
Workshop II:
The Loop Club
p. 27
p. 28
p. 28
16.00
Coffee Break
17.00
Room C01
Room B05 – B07
p. 30
Room Saphir
Room A05 – A06
ISPAD Annual General Assembly
(ISPAD Members only)
p. 28
Room C01
18.00
19.00
20.00
Society’s Evening
incl. Award Ceremony
p. 28, 51
Deutsche Telekom Repräsentanz
21.00
Color Key
Satellite Symposia
Plenary Sessions / Symposia
Poster & Oral Sessions
www.ispad2007.com
* Please note that the Terumo
Breakfast Symposium, the
Plenary Plenary Sessions V and VI
will take place at the Radisson
SAS Hotel.
Social Events
General Assembly
15
08.00 – 09.30, Room C01
Notes
DAWN Youth Breakfast Symposium:
Changing the Future of Childhood Diabetes:
New Insights, New Commitments
Chairs: T. Danne, Hannover; H.-J. Aanstoot, Rotterdam
Youth Ambassadors: Breaking the Silence
Martin Salkow, Iurii Stasko, Anja Nielsen & Dana Lewis (Youth Ambassadors)
Introduction from co-Chairs
T. Danne, Hannover; H.-J. Aanstoot, Rotterdam
Momentum for Change: UNR07 & Youth Charter
T. Danne, Hannover; H.-J. Aanstoot, Rotterdam
Time for change: Advocating for improved psychosocial intervention
B. Anderson, Houston
DAWN Youth: Attitudes, Wishes and Needs of Children, Youth and Parents
S. Skovlund, Bagsvaerd
Making Change Happen: A Panel Discussion
T. Danne, Hannover; H.-J. Aanstoot, Rotterdam; B. Anderson, Houston;
J. Hitchcock, Hamilton and Youth Ambassadors (as named above)
Conclusions
T. Danne, Hannover; H.-J. Aanstoot, Rotterdam and
Youth Ambassadors (as named above)
A light breakfast will be served from 07.15 – 07.50.
10.00 – 11.00, Room C01
Notes
Opening Session:
Diabetes in Motion in the Year of the Child
Chair: O. Kordonouri, Hannover
Opening Remarks from the Conference President
O. Kordonouri, Hannover
President’s Welcome (German Diabetes Association)
T. Haak, Bad Mergentheim
President’s Lecture (International Society for Pediatric and Adolescent Diabetes)
S. Brink, Boston
State of the Art Lecture: Diabetes in Motion – Innovation, Economics and Ethics
E. Gale, London
16
www.ispad2007.com
Plenary Session I:
Cells & Drugs: New Approaches to Treatment
Chair: S. Brink, Boston
11.00 – 12.30, Room C01
Notes
Should we treat for more C-peptide?
A.-G. Ziegler, Munich
Stem cell transplantation in children with type 1 diabetes: How far are we?
C. Limbert, Würzburg
Facilitating regeneration of ‡-cells: A valid option for clinical treatment in
young people with diabetes?
M. Trucco, Boston
Poster Session I:
13.30 – 14.30, Room B08 – B09
Notes
For a listing of all posters, please see pages 32– 35 in this Program.
Posters in this session start with P/WED/01.
Plenary Session II:
Genes & Environment: New Approaches to Prevention
Chair: M. Knip, Helsinki
14.30 – 16.00, Room C01
Notes
Probiotics – from designer food to disease intervention
O. Vaarala , Helsinki
Vitamin D – from rickets to diabetes prevention
K. Badenhoop, Frankfurt
Metformin – slowing the accelerator?
T. Wilkin, Plymouth
Oral Presentation I:
Diabetes Care, Education, Psychosocial Issues
Chairs: L. Fisher, Los Angeles; A. Philotheou, Cape Town
16.30 – 18.00, Room C01
Notes
O/WED/1/01
The Clinical Trial of Metformin in Children and Adolescents with
Type 2 Diabetes Mellitus, T2DM in Japan
S. Amemiya, N. Matsuura, S. Sugihara, Y. Yokota, T. Tanaka, H. Nakamura,
the Study Group of the Pediatric Clinical Trial of Metformin
O/WED/1/02
Age, Insulin Regimen and HbA1C: The Search for Diabetes in Youth Study
C. Pihoker, C. Paris, G. Imperatore, A. Ruggiero, B. Rodriguez, I. D. Schwartz,
G. Klingensmith, SEARCH for Diabetes in Youth
www.ispad2007.com
17
continued
O/WED/1/03
A Comparative Study of an Experimental 4 mm Needle and Novofine® 6 mm Needle
in Relation to Anatomical Deposition of Sterile Air in Lean Diabetic Children
N. Birkebaek, J. Solvig, A. Elbæk, P. Bonde, C. Jørgensen, J. Smedegaard
O/WED/1/04
Insulin Omission and Glycaemic Control in Adolescents with Type 1 Diabetes
from 21 International Centres
S. E. Skovlund, C. de Beaufort, T. C. Skinner, P. Swift, On Behalf of the Hvidoere
Study Group
O/WED/1/05
Assessing the Needs of Children with Diabetes in the School
B. Amillategui, P. Giralt, M. C. Marin, E. Mora, S. García-Bouza, R. Arana
O/WED/1/06
Monitoring Health-Related Quality of Life in Adolescents with Type 1 Diabetes
Improves Psychosocial Health and Satisfaction with Care
M. de Wit, H. Delemarre-van de Waal, J. A. Bokma, K. Haasnoot, M. Houdijk, R. Gemke,
F. Snoek, DiaQuest Study Group
O/WED/1/07
Quality of Life in Children with Type 1 Diabetes and Psychological Burden in Parents during the First Year after Diabetes Onset: A Prospective Multicentre Study
K. Lange, T. Kleine, D. Dunstheimer, J. Etspüler, D. Paape, R. Lauterborn, N. Jorch,
T. Kapellen, M. Petersen, K.-H. Ludwig, E. Serra, T. Danne
O/WED/1/08
Parent Well-Being and Support are Associated with Better Metabolic Control
and Quality of Life in Adolescents with Type 1 Diabetes
H. M. C. V. Hoey, P. Swift, C. de Beaufort, T. C. Skinner, S. E. Skovlund, F. Cameron,
for the Hvidoere Study Group on Childhood Diabetes
O/WED/1/09
Evaluation of a Transition to Adult Diabetes Care Program for Youth with
Type 1 Diabetes (TID) and their Parents
M. Frank, M. Small, K. Perlman
16.30 – 18.00, Room B05 – B07
Notes
Oral Presentation II:
Immunology and Genetics of Diabetes
Chairs: O. Cinek, Prague; M. Rewers, Colorado
O/WED/2/01
Specific Immune Response to GAD65 in Type 1 Diabetic Children Treated with
GAD65 (Diamyd™)
J. Ludvigsson, R. Casas, M. Hedman, S. Axelsson, M. Faresjö
18
www.ispad2007.com
O/WED/2/02
GAD65-Vaccination Preserves Residual Insulin Secretion in Children and
Adolescents with Recent Onset Type 1 Diabetes; Results of a Randomized
Controlled Phase II Trial
J. Ludvigsson, O. Vaarala, G. Forsander, S. Ivarsson, C. Johansson, A. Lindh,
N.-Ö. Nilsson, J. Åman, E. Örtquivst, J. Robertsson, R. Casas
continued
O/WED/2/03
Age is the Most Important Factor for the Decline in Beta Cell Function during
the First Year after Diagnosis of Childhood Type 1 Diabetes
H. B. Mortensen, S. Pörksen, P. Hougaard, E. Schönle, P. Swift, M. Kocova, L. Hansen,
Hvidøre Study Group on Childhood Diabetes
O/WED/2/04
Genetic Variation within the PPARγ2 Gene Associates with Residual Beta
Cell Function and Glycaemic Control in Children and Adolescents with Newly
Diagnosed Type 1 Diabetes during the first Year after Disease Onset
S. Pörksen, L .B. Nielsen, H. B. Mortensen, C. T. Ekstrøm, T. Danne, M. Kocova,
P. Martul, F. Pociot, P. Hougaard, S. Gammeltoft, M. Knip, L. Hansen,
Hvidøre Study Group on Childhood Diabetes
O/WED/2/05
The Risk of Celiac Disease among Children with Diabetes has Increased
Three-Fold Over the Last Ten Years
O. Cinek, M. Kulich, G. Deja, O. Kordonouri, N. Bratanic, E. Froehlich-Reiterer,
J. Vosahlo, E. Schober, Z. Sumnik
O/WED/2/06
GADA Positive Children and Adolescents with Type-1 Diabetes (T1D) have an
Increased Risk of Autoimmune Thyroiditis (AIT)
O. Kordonouri, N. Meyer, R. Hartmann
O/WED/2/07
Two Families with a Novel H241q Mutation in NEUROD1 Causing MODY6 Diabetes
° hová, J. Ek, T. Pelikánová, O. Pedersen, T. Hansen, O. Cinek
J. Lebl, L. Gonsorčíková, Š. Pru
O/WED/2/08
Protection against Diabetes: Application of Coppering Lowering Effect
of Tetrathiomolybdate
C. Zeng, G. Hou, G. J. Brewer, R. Dick
O/WED/2/09
Genetic Protection from Metabolic Syndrome in Young Girls:
APM1 -11,391G>A Polymorphism
A. Morandi, L. Pinelli
www.ispad2007.com
19
18.30 – 19.30, Room C01
Opening Ceremony
Notes
Welcome Messages
Conference Highlights
19.30 – 20.30, Level B / C
Welcome Reception
Notes
Get Together
Meet old friends and make new ones while
enjoying a selection of specialty dishes.
07.30 – 08.30, Room C01
Notes
Eli Lilly & Company Breakfast Symposium:
Our Children with Diabetes: Hearts at Risk
Chair: M. Tan, USA
Welcome and introduction of speakers
M. Tan, USA
Our children with diabetes: Hearts at risk
F. Kaufman, USA
Question and Answer Session
Closing summary
M. Tan, USA
A light breakfast will be served before the symposium.
07.30 – 08.30, Rooms A03/A04/A05/A06
Notes
(Advance Registration Required)
Infusion Sets: as diverse as the kids you treat! Set selection, site management
and solving common problems
Room A03
Solving the puzzle of glucose patterns is child’s play! CareLink™ Therapy
Management Software and its role in Diabetes Management
Room A04
20
www.ispad2007.com
Know what your kids are up to! Continuous Glucose Monitoring to optimize
Diabetes Management in children
Room A05
continued
Pump up your practice! Reaching treatment targets with Sensor-Augmented
Insulin Pump Therapy
Room A06
A light breakfast will be served after the workshops.
Symposium:
New Kids on the Block: Adipocytokines for Pediatric Endocrinologists
Chair: W. Kiess, Leipzig
09.00 – 10.30, Room C01
Notes
Genes and type 2 diabetes: How far is genetic screening for children?
C. Polychronakos, Montreal
Separating fact from fiction through translational research:
Leptin and adiponectin from bench to bedside
C. Mantzoros, Boston
What does the future hold? Clinical applications of adipocyte secreted hormones
S. Blüher, Leipzig
EURODIAB@ISPAD Symposium:
Recent Trends in Epidemiology
Chairs: S. Brink, Boston; C. Bartsokas, Athens
09.00 – 10.30, Room B05 – B07
Notes
15 year trends of the incidence of type 1 diabetes in Europe
C. Patterson, Belfast
Global epidemiology of non-type 1 diabetes
G. Soltesz, Pecs
Diabetic nephropathy and childhood onset diabetes –
Is there epidemiological evidence for optimism?
G. Dahlquist, Umeå
IDF@ISPAD Symposium:
DKA Prevention at Onset: How to Achieve the Goal?
Chairs: H.-J. Aanstoot, Rotterdam; F. Kaufman, Los Angeles
11.00 – 12.30, Room C01
Notes
DKA as health problem in the year of the child
J. Edge, Oxford
DKA prevention in the primary care setting
M. Vanelli, Parma
www.ispad2007.com
21
continued
Reducing DKA at onset – how to monitor success?
A. Neu, Tübingen
11.00 – 12.30, Room Room B05 – B07
ESPE@ISPAD Symposium:
Diabetes & Puberty: Mechanistic Views
Chairs: O. Hiort, Lübeck; L. Fisher, Los Angeles
Notes
Androgens and diabetes
D. Dunger, Cambridge
Oestrogens and diabetes
E. Codner, Santiago
Insulin resistance during puberty: Is it good or bad?
S. Arslanian, Pittsburgh
12.30 – 13.30, Rooms A03/A04/A05/A06
Notes
Room A03
Room A04
Room A05
Room A06
A light lunch will be served after the workshops.
13.30 – 15.00, Room C01
Notes
Plenary Session III:
Educating the Educators: Key Factors for Successful Programs
Chairs: A. Delamater, Miami; M. Frank, Toronto
Lestradet Lecture
Prize Winner – ISPAD Lestradet Award for Education and Advocacy
Family involvement in the management of the child’s diabetes
B. J. Anderson, Houston
Individualized diabetes education in pediatrics
K. Lange, Hannover
22
www.ispad2007.com
Social Afternoon
15.30 – 23.00
Notes
Boat Trip & Garden Party
Please see page 50 – 51 for details
Roche Diagnostics Breakfast Symposium:
Contributors to a Good Diabetes Management for the Young
Chair: P. Adolfsson, Göteborg
07.30 – 08.30, Room C01
Notes
Introduction
P. Adolfsson, Göteborg
The German experience with pumps for the very young –
What does it need to be good?
B. Heidtmann, Hamburg
What is the doctor’s contribution for a good therapy with pumps?
R. Hanas, Uddevalla
Do fewer injections mean less damage done? Psychosocial aspects
of CSII in adolescents
J.-P. Kay, Hamburg
Discussion and closing remarks
P. Adolfsson, Göteborg
07.30 – 08.30, Rooms A03/A04/A05/A06
Notes
Room A03
Room A04
Room A05
www.ispad2007.com
23
continued
Room A06
A light breakfast will be served after the workshops.
09.00 – 10.30, Room C01
Notes
Plenary Session IV:
Great Beginnings: Neonatal Origins of Later Diabetes
Chairs: D. Daneman, Toronto; C. Acerini, Oxford
ISPAD Young Investigator’s Lecture
Prize Winner – ISPAD Young Investigator Award
Perinatal programming and risk of later disease
J. Dötsch, Erlangen
The fetal origins of the metabolic syndrome: the case of the Haguenau cohort
C. Levy-Marchal, Paris
11.00 – 12.30, Room C01
Notes
Oral Presentation III:
Diabetes Acute and Chronic Complications
Chairs: C. Acerini, Oxford; J. Wolfsdorf, Boston
O/FRI/1/01
Further Insights into the Mechanisms and Effects of Brain Injury
in Diabetic Ketoacidosis
I. Koves, T. Inder, M. Wellard, M. Mackay, M. Ditchfield, L. Coleman,
M. Kean, G. Werther, E. Northam, F. Cameron
O/FRI/1/02
Comparison of 2 Protocols for Treatment of Diabetic Ketoacidosis in Children
with T1D
E. Petraikina, E. Pronina, I. Rybkina, T. Mikhailova, E. Mandzhieva, V. Piliutik
O/FRI/1/03
Diabetic Nephropathy in 27,643 Children, Adolescents and Adults with Type 1
Diabetes: Effect of Diabetes Duration, Hba1c, Hypertension, Dyslipidemia,
Diabetes Onset and Gender. Analysis from the Prospective German Diabetes
Documentation and Quality Management System (DPV)
K. Raile, A. Herbst, D. Dunstheimer, P. Busch, S. Hofer, R. W. Holl
O/FRI/1/04
Arterial Hypertension and Prehypertension in Children and Adolescents
with Type 1 Diabetes
L. Machnica, G. Deja, K. Tucholski, E. Skal/a
24
www.ispad2007.com
O/FRI/1/05
Insulin Binding to Antibodies is a Risk Factor for Inexplicable Severe
Hypoglycaemia in Children with Type-1 Diabetes Mellitus
O. Seewi, C. Jaeger, R. G. Bretzel, E. Schönau
continued
O/FRI/1/06
The Glucagon Response to Hypoglycaemia is Lost Early in Adolescents with
Type 1 Diabetes Mellitus and not Preserved by Strict Glycaemic Control Initiated
at Diagnosis
A. Siafarikas, N. Ratnam, V. Baker, D. Marangou, J. Loveday, M. Le Page, J. Elliott,
M. K. Bulsara, T. W. Jones, E. A. Davis
O/FRI/1/07
Screening for Diabetic Retinopathy by Nonmydriatic Retinal Imaging
A. Saporiti, T. Cardelli, R. Cardani, S. Chiaravalli, G. Bianchi, C. Azzolini, A. Salvatoni
O/FRI/1/08
Transcutaneous Electrical Nerve Stimulation in Paediatric Patients with Painful
Diabetic Neuropathy
S. Kalra, B. Kalra, A. Sharma
O/FRI/1/09
Association between Leu54Met Polymorphism at the Paraoxonase Gene (PON1)
and Plantar Fascia Thickness in Young Patients with Type 1 Diabetes
P. H. Gallego, A. Duffin, M. E. Craig, B. Bennetts, A. J. Jenkins, J. Cusumano, A. Lam,
K. C. Donaghue
Oral Presentation IV:
Beta Cell and Adipocyte Function, New Insulins
Chairs: J. Ludvigsson, Linkøping; M. Phillip, Tel Aviv
11.00 – 12.30, Room B05 – B07
Notes
O/FRI/2/01
Can we Build a Beta Cell? Induction of Beta Cell Genes in Transcription-Factor
Targeted Cells
L. Levitsky, J. Huang, D. Rhoads
O/FRI/2/02
Effect of A20 Gene on Animal Pancreas Islet Xenotransplant
D. Zhi, S. Shen, Z. Lu
O/FRI/2/03
In-Vitro (Re)programming of Human Bone Marrow Stromal Cells towards Insulin
Producing Phenotypes
C. Limbert, R. Ebert, G. Päth, M. Kassem, F. Jakob, J. Seufert
O/FRI/2/04
Improvements in Cognition with Insulin Pump Therapy in Children with
Type 1 Diabetes Mellitus (T1DM)
S. J. Knight, F. Cameron, E. Northam, S. Donath, A. Gardner, P. Joy, G. Ambler
www.ispad2007.com
25
continued
O/FRI/2/05
Novel Adipokines Retinol Binding Protein-4 and Lipocalin-2 in Childhood
Obesity: Differences from Adult Obesity
C. Kanaka-Gantenbein, A. Margeli, P. Pervanidou, S. Sakka, I. Papassotiriou, G. Chrousos
O/FRI/2/06
Serum Adiponectin and Expression of AdipoR1, PPAR-γ and CB1 in Primary Adipocyte Cultures from Abdominal Adipose Tissue of Lean Pre-Pubertal Children
A. Karvela, A. P. Rojas-Gil, A. Pappa, H. Pappadaki, E. Samkinidou, J. Varakis,
G. Georgiou, B. E. Spiliotis
O/FRI/2/07
Differences in Waist Circumference and Expression of AdipoR1, PPAR-γ and CB1
in Primary Adipocyte Cultures from Abdominal Adipose Tissue of Obese and Lean
Pre-Pubertal Children
A. Karvela, A. P. Rojas-Gil, A. Pappa, H. Pappadaki, E. Samkinidou, J. Varakis, G. Georgiou
O/FRI/2/08
Long-Acting Insulin Analogues Have Mitogenic and Antiapoptotic Activities
D. Weinstein, H. Werner, Z. Laron
O/FRI/2/09
Changes in the Use of Analogue Insulins in 33944 Children and Adolescents
with Type 1 Diabetes in 254 German Centers in the Last Ten Years
T. Kapellen, J. Wolf, R. Stachow, R. Ziegler, R. Szczepanski, R. W. Holl, DPV Wiss Study
Group, Germany
11.00 – 12.30, Room A01
Notes
Symposium:
Politics and Pediatric Diabetes: How to Ensure Equal Standards
of Care – The European Example
Chairs: C. de Beaufort, Luxembourg; J. Bowis, Member of the European Parliament, Brussels
Stakeholder initiatives addressing the pediatric diabetes challenge in Europe
T. Danne, Hannover
The role of political advocacy from different perspectives:
The approach of FEND
A. Felton, UK
The approach of IDF Europe
M. Hall, UK
Current EU Initiatives:
Research
M. Hallen, European Commission, Brussels
Public Health
J. Waligora, European Commission, Brussels
26
Supported by an
Educational Grant
from Sanofi-Aventis.
www.ispad2007.com
Panel Discussion: How to ensure equal standards of care in Europe –
what role can the EU play?
J. Browis, MEP; M.Hall, IDF Europe; A. Felton, FEND; G. Roglic, WHO; T. Danne, ISPAD
continued
12.30 – 13.30, Rooms A03/A04/A05/A06
Notes
Room A03
Room A04
Room A05
Room A06
A light lunch will be served after the workshops.
Poster Session II
13.30 – 14.30, Room B08 – B09
Notes
For a listing of all posters, please see pages 36 – 39 in this Program.
Posters in this session start with P/FRI/01
Symposium:
Update on the ISPAD Clinical Practice Consensus Guidelines 2006/2007 –
What Has Been Done and What Will Have to be Done?
Chairs: P. Swift, Leicester; K. Donaghue, Sydney
14.30 – 16.00, Room C01
Notes
Introduction
R. Hanas, Uddevalla
Monitoring targets for blood glucose and for HbA1c
M. Rewers, Colorado
Hypoglycaemia treatment
R. Hanas, Uddevalla
Nutrition: Insulin to carbohydrate ratio
C. Smart, Newcastle
Fluid and insulin for surgery and DKA
J. Wolfsdorf, Boston
www.ispad2007.com
27
continued
When to screen for long-term complication?
K. Donaghue, Sydney
How to approach the less well developed world and ‘minimum standards’?
D. Daneman, Toronto
Will the UNITE for diabetes IDF Charter help convert guidelines into practice?
P. Swift, Leicester
14.30 – 16.00, Room B05 – B07
Notes
Workshop I:
Is Carbohydrate Counting Essential for Successful Treatment?
Chair: J. Ludvigsson, Linkøping
Introduction to the topic
J. Ludvigsson, Linkøping
Carbohydrate Counting: What is the evidence?
S. Waldron, Dorset
Carbohydrate Counting: How to educate?
R. Lauterborn, Berlin
14.30 – 16.00, Room A05 – A06
Notes
Workshop II:
The Loop Club
Chair: M. Phillip, Tel Aviv
Introduction to the topic
M. Philip, Tel Aviv
Glucose variability: How to measure?
P. Hindmarsh, London
Glucose variability: How to treat?
D. Deiss, Berlin
16.30 – 18.00, Room C01
ISPAD Annual General Assembly
(ISPAD Members only)
19.30 – 24.00
Society’s Evening
Notes
At the Deutsche Telekom Repräsentanz, including the ISPAD Awards Ceremony
Please see page 51 for details
28
www.ispad2007.com
Terumo Breakfast Symposium:
Decreasing Pain in Children with Diabetes
Chair: Y. Uchigata, Tokyo
07.30 – 08.30, Radisson SAS Hotel, Room Saphir
Notes
The role of pain in a survey on self-monitoring of blood glucose in Japan
Y. Uchigata, Tokyo
Measuring pain in children
K. Lange, Hannover
Injection pain in children with diabetes
R. Hanas, Uddevalla
Experience with hollow-bore lancets in children with diabetes
T. Danne, Hannover
Discussion
Plenary Session V:
5th Symposium on Diabetic Angiopathy in Children
Glycemic Targets to Prevent Complications in Children
Chairs: T. Danne, Hannover; D. Becker, Pittsburgh
Notes
Lessons from DCCT and EDIC: The role of glycemic memory
N. H. White, St. Louis
Do we need age-dependent glycemic targets? – The ADA and Canadian perspective
M. Rewers, Colorado
Do we need age-dependent glycemic targets? – The European perspective
T. Danne, Hannover
Plenary Session VI:
5th Symposium on Diabetic Angiopathy in Children
Early Recognition and Early Treatment of Late Complications in Children –
Where Are We Now?
Chairs: L. Madacsy, Budapest; O. Kordonouri, Hannover
Notes
Molecular mechanisms and early treatment options of diabetic retinopathy
H.-P. Hammes, Mannheim
Predictors of diabetic nephropathy: How to diagnose and when to treat?
D. Daneman, Toronto
Autonomic and peripheral neuropathy: Is it relevant in pediatrics?
K. Donaghue, Sydney
www.ispad2007.com
29
continued
Macroangiopathy kills in type 1 and type 2 diabetes: Lessons for pediatrics?
T. Reinehr, Datteln
Closing Session
Chairs: L. Fisher, Los Angeles; T. Danne, Hannover
Notes
Official Closing Session of ISPAD 2007, incl. handover ceremony to ISPAD 2008
13.30, Radisson SAS Hotel, Room Saphir
Farewell Lunch
Notes
30
www.ispad2007.com
BRAND NEW!
Development of the Pancreas and
Neonatal Diabetes
Endocrine Development
Editor: P. Mullis
Vol. 12
Development
of the Pancreas and
Neonatal Diabetes
Tentative Contents
Editors
w w w . k a r g e r. c o m / e n d e v
J.P. Hamilton-Shield
R. Scharfmann
!
NEW
Pancreatic Development as a Basis for the
Definition of New Therapies for Diabetes:
Scharfmann, R.
Overview of Neonatal Diabetes:
Hamilton-Shield, J.P.
Endocrine Development, Vol. 12
ISSN 1421–7082
New Series Editor: Mullis, P. (Bern)
Development of the Pancreas and Neonatal Diabetes
Editors: Hamilton-Shield, J.P. (Bristol); Scharfmann, R. (Paris)
approx. 200 p., hard cover, appearing 3rd quarter 2007
approx. CHF 188.– / EUR 134.50 / USD 171.00
Prices subject to change
EUR price for Germany, USD price for USA only
ISBN 978–3–8055–8385–5
Duvillié, B.
Functional Imaging of the Pancreas: the Role
of [18F]Fluoro-L-DOPA PET in the Diagnosis of
Hyperinsulinism of Infancy: Ribeiro, M.-J.
Tubiana-Rufi, N.
Generating New Candidate Genes for Neonatal
Diabetes: Functional and Genetic Studies of
Insulin Secretion in Type 2 Diabetes: Rutter, G.
Diabetes in Very Young Children and Mutations in
the Insulin Secreting Cell Potassium Channel
Genes: Therapeutic Consequences: Polak, M.
Imprinting in Human Disease with Special
Reference to Transient Neonatal Diabetes
and Beckwith-Wiedemann Syndrome:
Temple, K.I.
The Physiology and Clinical Management of
Glucose Metabolism in the Newborn:
Beardsall, K.
Congenital Endocrinopathies
Endocrine Development
Editor: M.O. Savage
Vol. 11
New Insights into Endocrine Diseases and Diabetes
Congenital
Endocrinopathies
Tentative Contents
New Insights into Endocrine
Diseases and Diabetes
Editors
Lorini, R.
Maghnie, M.
D‘Annunzio, G.
Loche, S.
Savage, M.O.
Transcription Factors in Pancreatic Development
(Animal Models): Gradwohl, G.
Distinct Roles of HNF1␤, HNF1␣, and HNF4␣
in Regulating Pancreas Development, ␤-cell
Function and Growth: Ferrer, J.
In vivo and in vitro Techniques to Study
Pancreas Development and Islet Cell Function:
Insulin Pump Therapy in Neonatal Diabetes:
NEW
!
Endocrine Development, Vol. 11
ISSN 1421–7082
Series Editor: Savage, M.O. (London)
Congenital Endocrinopathies
Editors: Lorini, R. (Genova); Maghnie, M. (Genova);
D‘Annunzio, G. (Genova); Loche, S. (Genova); Savage, M.O.
(London)
approx. 200 p., hard cover, appearing 3rd quarter 2007
ISBN 978–3–8055–8347–3
Genomic Approaches in Genetic Research for
Endocrine Diseases: Ravazzolo, R.
Genetic Defects of the GH-IGF Axis Associated
with GH Insensitivity: Woods, K.
Late Effects of Disturbed IGF Signaling in
Congenital Diseases: Intrauterine and Postnatal
Growth Retardation: Cianfarani, S.;
Geremia, C.; Puglianiello, A.; Maiorana, A.;
Germani, D.
Growth Hormone Receptor Polymorphisms:
Controversies and Outcome of GH Treatment:
Buzi, F.; Mella, P.; Pilotta, A.; Prandi, E.;
Lanfranchi, F.; Carapella, T.
Genetic Disorders Involving Adrenal Development:
Achermann, J.C.; Lin, L.; Ferraz-de-Souza, B.
Early Management and Gender Assignment in Disorders of Sexual Differentiation: Hughes, I.A.
Prenatal and Early Postnatal Treatment of
Congenital Adrenal Hyperplasia: Ghizzoni, L.;
Cesari, S.; Cremonini, G.; Meandri, L.
Neonatal Diabetes: The Role of KCNJ11 (Kir6.2):
Tammaro, P.
Diagnosis of Neonatal and Infancy-Onset
Diabetes: Barbetti, F.
Management of Neonatal and Infancy-Onset
Diabetes Mellitus: Njølstad, P.R.; Søvik, O.;
Tansek, M.Z.; Sagen, J.V.
Insights in Congenital Hyperinsulinism: Hussain, K.
A Clinical Approach to Severe Insulin Resistance:
Savage, D.B.; Semple R.K.; Chatterjee, V.K.K.;
Wales, J.K.H.; Ross, R.J.M.; O’Rahilly, S.
Inherited Endocrine Diseases Involving G Proteins
and G Protein-Coupled Receptors: Spiegel, A.M.
Stem Cells: From Animal Research to Clinical
Application: Redi, C.A.; Monti, M.; Merico, V.;
Neri, T.; Zanoni, M.; Garagna, S.; Zuccotti, M.
(/2-/.%
Orde r Fo rm
Keep informed about pediatric endocrinology: Read 2%3%!2#( at www.karger.com/hre
Please send:
쎱 copy/ies: Development of the Pancreas and
Neonatal Diabetes
Editors: Hamilton-Shield, J.P. (Bristol);
Scharfmann, R. (Paris)
approx. 200 p., hardcover, appearing 3rd quarter 2007
ISBN 978–3–8055–8385–5
쎱 copy/ies: Congenital Endocrinopathies
Editors: Lorini, R. (Genova); Maghnie, M. (Genova);
D‘Annunzio, G. (Genova); Loche, S. (Genova);
Savage, M.O. (London)
approx. 200 p., hardcover, appearing 3rd quarter 2007
ISBN 978–3–8055–8347–3
Payment:
(Postage and handling free with prepayment)
Please charge to my credit card
American Express Diners
Visa
Euro-, MasterCard
Fax: +41 61 306 12 34
S. Karger AG, P.O. Box, CH–4009 Basel (Switzerland)
E-Mail orders@karger.ch, www.karger.com
Name/Address:
Card No.:
Exp. date:
CVV/CVC:
(3 digits in the signature field on the back of VISA and Mastercard)
Check enclosed
Please bill me
Orders may be placed with any bookshop, subscription agency,
directly with the publisher or through a Karger distributor.
Date:
Signature:
KI 07689
Poster Sessions
Poster Sessions
Poster Exhibition Map
The poster exhibition will be located in the room B08 – B09. The posters will
be present during the whole conference. Two Poster Sessions with designated
chairmen will take place:
Poster Session I, Wednesday September 26, 13.30 – 14.30, room B08 – B09
Poster Session II, Friday September 28, 13.30 – 14.30, room B08 – B09
Posters have been handed in and accepted in the following categories:
Intensified Insulin Treatment, Pumps and Sensors III
P/FRI/87 – P/FRI/96
New Insulins and Pharmacologic Agents
Intensified Insulin Treatment, Pumps and Sensors II
P/WED/77 – P/WED/86
Miscellaneous II
Poster Category
Abstracts
Intensified Insulin Treatment, Pumps and Sensors I
Diabetes Acute and Chronic Complications I
Diabetes Acute and Chronic Complications II
Diabetes Acute and Chronic Complications III
– Education
– Insulin Therapy and Metabolic Control
– Nutrition and Quality of Care
– Psychological and Psychosomatic Aspects
– Quality of Life
Epidemiology of Diabetes
Intensified Insulin Treatment, Pumps and Sensors I
Intensified Insulin Treatment, Pumps and Sensors II
Intensified Insulin Treatment, Pumps and Sensors III
Miscellaneous I
Miscellaneous II
Monogenic Forms of Diabetes
Type 2 Diabetes, Diabetes and Obesity I
Type 2 Diabetes, Diabetes and Obesity II
Miscellaneous I
Diabetes Care, Education, Psychosocial Issues –
Nutrition and Quality of Care
Quality of Life
Diabetes Care, Education, Psychosocial Issues – Education
Insulin Therapy and Metabolic Control
Psychological and Psychosomatic Aspects
j Entrance
32
www.ispad2007.com
Poster Session I
– Psychological and Psychosomatic Aspects
– Education
Chairs: A. Delamater, Miami; S. Waldron, Leicester
Chairs: H. Dorchy, Brussels; M. Frank, Toronto
Chairs: W. Burger, Berlin;
A. Vazeou-Gerasimidi, Athens
P/WED/01 Psychological and Psycosomatical
Approach in Adolescents with
Juvenile Diabetes
E. Gkika, C. Bartsocas, C. Synodinou
P/WED/11
Diabetes Mellitus Type 1:
Problems of Training of Children
N. Filina, N. Bolotova, N. Nikolaeva
P/WED/21
P/WED/12
Implementation of a Teaching
Program for Diabetes in Schools
N. Armstrong
P/WED/02 Is Art Therapy a Supportive Intervention
for Adolescents with Type 1 Diabetes?
V. Alexander, N. Bywater, P. Boyle,
J. McCulloch, G. Humphris, G. McFarland,
S. Greene
P/WED/03 Diabetes Camp for Those with Poor
Metabolic Control; Evaluation of
HbA1c, Self-Confidence, Locus of Control and Amount of Physical Exercise
P. Adolfsson, F. Sundberg, K. Wiberg,
P. Sand, J. Chaplin
P/WED/04 Behavioural Problems in Type 1
Diabetics in India
R. Shukla, D. Yagnik
P/WED/05 Self-Injurious and Suicidal Behavior
in Slovenian Adolescents with
Type 1 Diabetes
N. Ursic Bratina, M. Radobuljac,
M. Tomori, T. Battelino
P/WED/06 Cognitive and Emotional Disorders
in Children with Diabetes Mellitus
O. Chapova
P/WED/07 Gender Differences in Compliance
and Psychosocial Factors among
Adolescents with Insulin Dependent
Diabetes Mellitus
M. Thastum, A. Schnieber, A. Mose,
N. Birkebæk
P/WED/08 Prevalence and Persistence of
Disturbed Eating Behavior and
Eating Disorders in Girls with Type 1
Diabetes Mellitus
P. Colton, G. Rodin, M. Olmsted, A. Rydall,
D. Daneman
P/WED/09 „Chronic Sorrow“ in Parents of
Children with Type-1 Diabetes
R. Ziegler, S. Wiedebusch, F. A. Muthny
P/WED/10 Evaluate the Problem of Marriage
in Type 1 Diabetics in India
D. Yagnik, R. Shukla
P/WED/13
Managing Diabetes in Children:
“From Prescription to Empowerment:
A Comprehensive Approach”
A. Gupta, S. Rajput, M. Sandhu, A. Sen
P/WED/14 To Balance Decision-Making
Competence and Parent Involvement
in Empowerment Education in
Teenagers with Diabetes
G. Viklund, K. Wikblad
P/WED/15
Training Programs for Obese Children
with Metabolic Syndrome
J. Zotova, N. Bolotova, A. Averyanov
P/WED/16 Patients and Parents’ Diabetes
Mellitus Type I Knowledge Degree
and its Correlation with Haemoglobin
A1C Value
C. Costa, S. Carvalho, C. Correia,
M. Fontoura
P/WED/17
Diabetes Self-Care: The Perspectives
and Experiences of Children and
Adolescents
D. Koller, D. Daneman, S. Barrett, M. Small
Eye and Renal Complications in Type 1
Diabetes Mellitus in National Hospital
of Pediatrics in Hanoi – Vietnam
H. T. Nguyen, P. T. Bui, T. M. H. Vo
P/WED/22 Onset of Late Complications is Heavily
Influenced by the Characteristics of
Postinitial Remission in Children with
Type 1 Diabetes
A. Körner, P. Toth-Heyn, L. Madacsy,
D. Garan
P/WED/23 Acute Complications Continue as a
Major Cause of Death for Children
and Young Adults with Type 1 Diabetes
R. Feltbower, H. J. Bodansky, C. Stephenson,
C. Patterson, R. Parslow, F. Campbell,
P. McKinney
P/WED/24 Diabetic Ketoacidosis among Children
with Established Type 1 Diabetes
during one Year at a Norwegian
University Hospital
B. J. Bækkelie, J. Larsen
P/WED/25 Oxidative Stress is Increased in Type-1
Diabetic Children with Good Glycaemic
Control and Glomerular Hyperfiltration
C. del Castillo Villaescusa, S. Pons Morales,
R. Hernández Marco, V. Valls Bellés,
P. Codoñer Franch
P/WED/18 Effectiveness of Educational Intervention with Snake and Ladder Board
Game in Children with Type 1 Diabetes
S. Kalra, S. Nagpal, B. Kalra
P/WED/26 Evaluation of the Benefits of Regular
Exercise on Glycemic Control and
on Potentially Acute Risks (Diabetic
Ketoacidosis, Rate of Severe Hypoglycemia) in Children with Diabetes Type 1
A. Herbst, B. Heidtmann, K. Raile, R. Holl,
for the DPV-Science Initiative
P/WED/19 The Usefulness of Continuous Glucose
Monitoring as an Educational Tool for
the Improvement of Glycemic Control
in Children and Adolescents with
Diabetes Type 1
C. Kanaka-Gantenbein, O. Fafoula,
M. Pavlatou, S. Sakka, G. Chrousos
P/WED/27 Children Presenting in DKA at
Diagnosis Have Higher Hba1c during
the Initial 8 Years of Type 1 Diabetes
Independently of Access to Care
and Ethnicity
A. Rewers, G. Klingensmith, A. Brown,
M. Rewers
P/WED/20 The Diabetes Rollercoaster –
Riding the Highs and Lows
R. Mulholland, P. E. Todd, C. E. Steele
P/WED/28 Diabetic Ketoacidosis in newly
Diagnosed Children in Relation
to Family History of Type 1 Diabetes
A. Hekkala, M. Knip, R. Veijola, and the
Finnish Pediatric Diabetes Register
P/WED/29 Neuropsychological Changes over a
6-Month Period in Children with Newly
Diagnosed Type 1 Diabetes Mellitus
(T1DM) and Diabetic Ketoacidosis (DKA)
M. Spencer-Smith, E. Northam, I. Koves,
T. Inder, G. Werther, M. Kean, M. Mackay,
L. Coleman, M. Wellard, M. Ditchfield,
F. Cameron
www.ispad2007.com
33
Poster Session I
Chairs: K. Donaghue, Sydney; J. Wolfsdorf, Boston
Chairs: C. Levy-Marchal, Paris; K. Pillay, Durban
Chairs: M. Herr, Berlin; F. Bonnici, Cape Town
P/WED/30 Gastric Emptying and its Relation to
Microalbuminuria in Children with
Type 1 Diabetes Mellitus
B. Ersoy, E. Bilgin, S. Can, V. Urk, O. Yilmaz,
D. Batok, M. Polat
P/WED/39 Simple Versus Sophisticated Measures
of Body Fat in Children and their
Relationship to Insulin Resistance
A. N. Jeffery, J. Hosking, B. S. Metcalf,
J. Roser, L. D. Voss, T. J. Wilkin,
The EarlyBird Study
P/WED/49 Diabetes Mellitus in Children
with Down’s Syndrome
S. Särnblad, S. Adolfsson, G. Forsander
P/WED/31
Relationship between Diabetic
Complications and Past Glycemic
Controls in the first Cohort of The
Japanese Study Group of Insulin
Therapy for Childhood and Adolescent
Diabetes (JSGIT)- Multi-Center
Prospective Analysis Y. Uchigata, N. Sasaki, S. Amemiya,
T. Urakami, T. Kawamura, S. Sugihara,
The Japanese Study Group of Insulin
Therapy for Childhood and Adolescent
Diabetes (JSGIT)
P/WED/32 Serum Lipids Profile Peculiarities in
Children with Diabetes Mellitus Type 1
E. Novikova, N. Bolotova, L. Skutchaeva
P/WED/33
Associated Pathology to Diabetes
Mellitus Type 1
G. M. Lou Francés, S. Soto de Ruiz,
M. Ferrer Lozano, Z. Galve Pradel,
M. Rodríguez Rigual
P/WED/34 The Role of Pro- and Anti-Angiogenic
Factors in the Angiogenesis Processes
in Children with Diabetes Mellitus
Type 1
K. Zorena, J. Myśliwska, M. Myśliwiec,
A. Balcerska
P/WED/35
Gastric Emptying and Postprandial
Glucose Excursions in Adolescents
M. Lodefalk, P. Bang, J. Åman
P/WED/36 Erythromelalgia Associated with
Acute Dibabetic Neuropathy in
Adolescent with Insulin-Dependent
Diabetes Mellitus
J. E. Lee, S. R. Kwon, S. K. Kim, Y. J. Hong
P/WED/37
Method of Correction of Autonomous
Nervous System Disorders in Children
with Diabetes Mellitus Type 1
N. V. Bolotova, V. Manukyan
P/WED/38 Reduced Baroreflex Gain is a Sign
of Early Autonomic Neuropathy
in Children with Type 1 Diabetes.
Preliminary Results
S. Riboni, G. V. Zuccotti, C. Mameli, D. Lucini,
M. Malacarne, L. Santoro, A. De Palma,
D. Spiri, A. Scaramuzza, M. Pagani
P/WED/40 Children and Adolescents with Type 2
Diabetes: Are Clinical Features Linked
to Presence of Autoantibodies?
T. Danne, M. Gottschalk,
S. Fuerst-Recktenwald
P/WED/41
Characteristics of the Metabolic
Syndrome is Prevalent in Children
with Newly Diagnosed Type 2 Diabetes
T. Urakami, A. Yoshida, J. Suzuki,
H. Saitoh, S. Morimoto, H. Mugishima
P/WED/42 Insufficient Compensation of Acute
Insulin Response to Glucose as an
Essential Pathogenesis in Japanese
Adolescent T2DM
K. Kobayashi, K. Nagamine, M. Mochizuki,
K. Kobayashi, N. Kikuchi, S. Amemiya
P/WED/43 Prevalence of Impaired Glucose
Tolerance and Type 2 Diabetes and
their Deteterminants in Obese Italian
Children and Adolescents
S. Arcano, B. Faggioli, G. L. Spadoni,
E. Del Duca, S. Piccinini, N. Rapini,
M. Porcari, M. L. Manca Bitti
P/WED/44 The Study of Screening for Type 2
Diabetes and Impaired Glucose Regulation in Children and Adolescents
C. Gong, B. Cao
P/WED/45 Compare the Practicability and Operability of Screening Protocol for T2DM
between Beijing Study Group Applied
and ADA Recommended
B. Cao, C. Gong
P/WED/46 Increased Adiposity after Diagnosis in
Italian Children with Type 1 Diabetes
Mellitus
G. d’Annunzio, N. Minuto, V. Emmanuele,
S. Mangini, V. Morsellino, A. Giannattasio,
F. Lugani, A. Pistorio, R. Lorini
P/WED/47 Roles of Diabetes and Obesity on Adiponectin Levels in Children and Adolescents with Type 1 Diabetes Mellitus
K. Nagamine, M. Mochizuki,
K. Kobayashi, K. Kobayashi,
K. Ohyama, S. Amemiya
P/WED/48 Validation of Percentiles for Insulin
Sensitivity Indexes in Healthy Caucasian Children: WBISI and HOMA-IR
R. Capanna, C. Giannini, T. de Giorgis,
V. Chiavaroli, F. G. Masuccio, E. D’Adamo,
A. Mohn, F. Chiarelli
34
P/WED/50 Cardiovascular Involvement in
Wolfram Syndrome
F. Lombardo, G. Salzano, F. L. De Luca,
L. Bruno, M. P. Calabrò, F. De Luca
P/WED/51
A Boy with Wolfram Syndrome
Presenting with Diabetes Mellitus
and Marked Polyuria, Bilateral
Hydronephrosis and Hydroureter
Mimicking Obstructive Uropathy
P. Nakavachara, A. Pattaragarn,
S. Likitmaskul, A. Sumboonnanonda
P/WED/52 Clinical Parameters for Molecular
Testing of Maturity Onset Diabetes
in the Young (MODY)
N. Datz, C. Nestoris, W. von Schütz,
T. Danne, A. J. Driesel, M. Maringa,
O. Kordonouri
P/WED/53
Maturity-Onset Diabetes of the Young
Type 3: A Case Report of a Female Child
Responsive to a Low Dose of Sulfonylurea
M. Jesic, S. Sajic, V. Zdravkovic,
M. Maringa, M. Jesic, D. Micic
P/WED/54 High Prevalence of TCF1 and NEUROD1
Common Variants in Combination
with GCK Mutations among Spanish
Children and Adolescents with MODY
Á. Campos-Barros, Ó. Rubio-Cabezas,
F. Díaz-González, K. E. Heath, J. Argente
P/WED/55 Permanent Neonatal Diabetes Mellitus –
Sulphonylureas Treatment
I. Micle, M. Marazan, O. Marginean,
E. Pop, R. Giurescu
P/WED/56 Activating Mutations in the KCNJ11
Gene Encoding the Kir6.2 Subunit
in Patients with Permanent Neonatal
Diabetes of Greek and Turkish
Cypriot Origin
I. S. Yiannis, N. Skordis, S. Ellard,
A. T. Hattersley
P/WED/57 Genetic Polymorphism of HLA Region
in Anti-Islet Autoantibody Seroconversion Observed in Permanent Neonatal
Diabetes Caused by Mutations in the
KCNJ11 Gene
A. Gach, A. Heinrich, M. T. Malecki,
K. Wyka, I. Klich, J. Bodalski, J. Sieradzki,
W. Mlynarski
P/WED/58 Family Report on two Siblings
Affected by Transient Neonatal
Diabetes – a Novel SUR1 Mutation
Inherited from the Father
S. Hofer, S. Flanagan, S. Ellard, E. Steichen
www.ispad2007.com
Poster Session I
Miscellaneous I
Chairs: H.-J. Aanstoot, Rotterdam; P. Swift, Leicester
P/WED/59 Clinical Profile and Autoantibody
Status in Younger Onset Diabetes
in Bangladesh
F. Mohsin, G. Hitman, D. Leslie, M. Hawa,
K. Biswas, B. Zabeen, N. Nahar, K. Azad
P/WED/60 Medication Induced Diabetes during
Treatment of Pre-B Cell and T-Cell ALL:
Prevalence, Risk Factors and Characteristics in a Population of ALL Patients at
the Hospital for Sick Children
D. Koltin, A. Naqvi, L. Sung, S. Urbach
P/WED/61 Neuronal Cells in Vitro Produce Taurine in Response to a Hyperosmolar
Environment – a Paradigm for Diabetic
Cerebral Oedema and its Therapy
I. Koves, V. Russo, F. Cameron, G. Werther
P/WED/62 HOMA and QUICKI Reflect Hepatic
but not Peripheral Insulin Action
in Adolescents
R. P. Hoffman
P/WED/63 International Diabetes Federation
“Life for a Child” Program
G. Ogle, M. Silink
P/WED/64 Month of Birth Seasonality in Children
with Celiac Disease Differs between
Genders and from that in the General
Population
Z. Laron, H. Meirson, H. Lewy
P/WED/65 Fulminant Onset (Japanese)
Type 1 Diabetes in a Caucasian Boy,
Triggered by Lyme Disease?
T. Mouraux, D. Roland, H. Dorchy
P/WED/66 Metabolic Health in UK Children
is Unrelated to Social Inequality
(The EarlyBird Diabetes Study)
L. Voss, J. Hosking, B. Metcalf, A. Jeffery,
D. Gardner, T. Wilkin, EarlyBird
Diabetes Study
Intensified Insulin Treatment, Pumps
and Sensors I
Chairs: E. Pańkowska, Warsaw; H. J. Veeze, Rotterdam
P/WED/67 Intensive Insulin Treatment in the
First four Years of Type 1 Diabetes
in Children
E. García-García, R. Galera, P. Aguilera,
M.-D. Gámez, J.-L. Gómez-Llorente,
A. Bonillo
P/WED/68 Carbohydrate to Insulin Matching
on a South African Urban Diet in
Adolescents with Type 1 Diabetes
M. Lorgat, L. Distiller, D. Segal
www.ispad2007.com
P/WED/69 Continuous Subcutaneous Insulin
Infusion Therapy in Children and
Adolescents with Diabetes Mellitus
Type 1: A Systematic Review
T. W. Gratzer, K. J. Jeitler, A. Berghold,
K. Horvath, T. R. Pieber, A. Siebenhofer
P/WED/70 Glycaemic Control in the First Two
Years of CSII Therapy in Children and
Adolescents with Type-1 Diabetes
D. Deiss, R. Hartmann, O. Kordonouri,
I. Stoelzel, R. Lauterborn, K. Raile
P/WED/71
Insulin Pump Therapy Versus Multiple
Insulin Injection in Type 1 DM
I. Velea, P. Ioan, C. Paul, L. N. Todorescu,
O. Velea
P/WED/72 Relationship Between Self-Monitored
Plasma Glucose (SMPG) and HbA1c
in Paediatric Subjects 4-18 Years of
Age with Type 1 Diabetes (T1D) Treated
with Continuous Subcutaneous
Insulin Infusion (CSII) Using Insulin
Aspart or Insulin Lispro
L. M. B. Laffel, C. Howard, C. T. Chang,
S. A. Weinzimer
P/WED/73
Effect and Safety of Continuous
Subcutaneous Insulin Infusion (CSII)
in Patients with Juvenile-Onset
Type 1 Diabetes-Indications for
Pump Therapy
J. Suzuki, H. Saitoh, S. Morimoto,
S. Kubota, T. Urakami, H. Mugishima
P/WED/74 In Children with Diabetes under
5 Years Old CSII Gives Significantly
Better Glycemic Control than Conventional Insulin Regimes without Side
Effects Such as Hypoglycemia
B. R. King, P. A. Crock, D. G. Anderson,
H. Phelan, C. E. Smart, E. Nunn,
M. Neylan, M. Fletcher
P/WED/75 Insulin Pump Therapy in Diabetic
Patients: The Results of 3 Years
Follow-Up
A. Emelyanov, V. Peterkova, T. Kuraeva
P/WED/76 Low Risk of Poor Metabolic Control
in Pre-Pubertal Diabetic Children
Treated with Insulin Pump. Results
of the Polish Prospective Pump Study
A. Szypowska, E. Pańkowska,
E. Czerniawska, B. Surdey, L. Lisowicz,
E. Kolender, M. Myśliwiec, on behalf
of the PolPedDiab group
Intensified Insulin Treatment, Pumps,
and Sensors II
Chairs: G. Rami, Vienna; T. Battelino, Ljubljana
P/WED/77 Meal-Type Rather than Bolus-Type
Determines Post-Prandial Glycaemia
in Children with Type 1 Diabetes on
M. O’Connell, H. Gilbertson, S. Donath,
F. Cameron
P/WED/78 Timing of Boluses in Children
with Type 1 Diabetes Using Insulin
Pump Therapy (TiBoDi Study).
Preliminary Results
A. Scaramuzza, D. Iafusco, L. Santoro,
A. Bosetti, S. Riboni, A. De Palma, D. Spiri,
C. Mameli, L. Pinelli, G. V. Zuccotti
P/WED/79 Dermatological Complications of
Insulin Pump Use in the Paediatric
Population
L. Conwell, E. Pope, A. Artiles, A. Mohanta,
A. Daneman, D. Daneman
P/WED/80 Measuring Quality of Life in Children
with Type 1 Diabetes Using Insulin
Infusion Pumps
L. Terrett, F. Campbell, P. Holland,
R. Feltbower
P/WED/81 Improvements in Mood and Behaviour
Following Commencement of Insulin
Pump Therapy in Children with Type 1
Diabetes Mellitus(T1DM)
G. Ambler, S. Knight, E. Northam,
S. Donath, A. Gardner, P. Joy, F. Cameron
P/WED/82 The Laboratory Evaluation of
Insulin Pumps
A. Martynov, A. Petraikin, D. Koshurnikov,
A. Rysakova, A. Zhuravlev, E. Petraikina,
O. Duchareva
P/WED/83 Imposing Exclusion Criteria for
Continuous Subcutaneous Insulin
Infusion (CSII) in Children is not
Clinically Justified
W. Lamb
P/WED/84 Insulin Pump Treatment in Children
and Adolescents: Our Criteria for
Introducing CSII
S. Hasanbegovic
P/WED/85 The Treament with Continuous
Subcutaneous Insulin Infusion
in Emila-Romagna
L. Iughetti, S. Zucchini, G. Chiari,
S. Cantoni, B. Predieri, T. Suprani,
L. Tarchini, P. Bruzzi, S. Salardi
P/WED/86 Characteristics of Paediatric Insulin
Pump Users in an Singaporean User
Financed Care Model
W. W. Lee, F. K. P. Yap, V. Oh, P. K. Lim,
W. C. Tan
35
Poster Session II
– Insulin Therapy and Metabolic Control
Chairs: A. Philotheou, Cape Town; L. Pinelli, Verona
P/FRI/01
P/FRI/02
P/FRI/03
Characteristics of Pediatric Pumpers in
Good vs. Suboptimal Metabolic Control
N. Ramchandani, I. Kazachkova,
S. Bhandari, S. Ten
A Prospective Study of Metabolic
Outcomes According to Method
of Insulin Delivery
W. Lamb
A Comparison of CSII vs MDI from the
Time of Diagnosis of Type 1 Diabetes
in Children <7 Years Old
N. Ramchandani, R. Purushothaman,
S. Sinha, M. Smotkin-Tangorra, S. Bhandari,
I. Kazachkova, H. Anhalt, S. Ten
P/FRI/04
Functional Insulin Therapy:
Experience in a French Paediatric
Diabetes Care Department
R. Reynaud, E. Alessandrini, G. Simonin
P/FRI/05
Medical Care Independent Factors
Related with Glycemic Control in
Children and Adolescencts with
Y. Ioannou S., T. Georgiou, T. Apsiotou,
S. Stavrou, N. Skordis
– Quality of Life
Chairs: K. Lange, Hannover; C. de Beaufort,
Luxembourg
P/FRI/11
P/FRI/12
The Burden of Having Diabetes.
An Overview of Children’s Needs
and Worries
B. Amillategui, M. C. Marin,
S. García-Bouza, P. Bodas, R. Arana
P/FRI/13
Adolescents and Young Adults
with Diabetes Type 1 at Camp-D:
Quality of Life, Metabolic Control
and Satisfaction with Long-Term
Care during the Phase of Transition
K. Lange, H. Sassmann, R. Landgraf,
T. Danne
P/FRI/14
P/FRI/06
P/FRI/07
P/FRI/08
P/FRI/09
P/FRI/10
Factors Influencing Glycemic Control
in Children and Adolescents with
Type 1 Diabetes in Two Belgian
University Hospital Centers
S. Van Aken, A. France, J. Vanbesien,
M. Craen, J. De Schepper
Metabolic Control in Type 1 Diabetes
- Evolution since 2001 to 2006
I. Dinis, N. Ana, S. Martins, A. Mirante
Metamorphoses in Childhood Type 1
Diabetes Mellitus in Romania between
Years 1998 and 2006
V. Serban, A. Vlad, A. Enache, A. Lacatusu,
L. Barna, S. Raceala Motoc, M. Mota,
ONROCAD Study Group
HbA1c in Children and Adolescents
with Type I Diabetes in Croatia
(2003-2005.) – Multicenter Study
A. Spehar Uroic, G. Stipancic, V. Skrabic,
K. Cvijovic, J. Ille, A. Radica, N. Rojnic
Putarek, M. Dumic
P/FRI/15
P/FRI/16
P/FRI/17
Health-Related Quality of Life
of Adolescents with Diabetes
Mellitus and those with Congenital
Hypothyroidism Detected by
Newborn Screening
H. Sato, N. Nakamura, S. Harada,
N. Matsuura, N. Sasaki
Diabetes Attitudes Wishes and Needs
(DAWN) in Polish Children and Youths
with Type 1 Diabetes Mellitus (T1DM)
in two Time Points: at the Onset
and after 1 Year T1DM Duration –
Cross-Sectional National Study
P. Jarosz-Chobot, G. Deja, M. ZegarlickaPoreba, W. Kot, A. Kokoszka, A. Noczynska
Functional Outcome in TIDM
12-15 Years after Disease Onset
E. Northam, D. Rankins, A. Lin,
G. Werther, F. Cameron
Children with Type 1 Diabetes within
the Greek School Environment
D. Karakaidos, P. Zosi, G. Triantafyllidis,
M. Vasiliadis, G. Kafalidis, E. Kaloudi,
C. Karis
P/FRI/18
Dawn Youth – a South African
Pilot Study
J. C. van Dyk
P/FRI/19
The Picture of Diabetes Issues in
Rural Population in Cameroon
J. N. Menang, M. P. Ful
Adolescents on Basal-Bolus Insulin
Can Fast during Ramadan
M. Al-Khawari, J. Allgrove
P/FRI/20
36
Quality of Life in Children and
Adolescents with Diabetes Mellitus
Type 1
N. Bolotova, O. Kompaniets,
A. P. Averyanov
Is Regular Tooth Brushing an Indicator
for a Healthier Lifestyle, Better Metabolic Outcome and Better Perception of
Health in Adolescents with Diabetes?
C. de Beaufort, C. Skinner, P. Swift,
on behalf of the Hvidoere Study Group
– Nutrition and Quality of Care
Chairs: G. Forsander, Gothenborg; R. Ziegler, Münster
P/FRI/21
A Successful Consortium between User
Group and Health Care Professionals
Equates to Good Glycaemic Control
A. Gupta, S. Kar, H. Alban Davies
P/FRI/22
Better Outcome in Type 1 Children
and Youth who Received their Care
in a Specialized Diabetes Center
form Onset Onwards Compared to
those Referred later from General
Pediatric Clinics
H. Veeze, I. Bliek, N. Rikkengaa,
M. Ruijgers, E. Aslander, H. Verkade,
H.-J. Aanstoot
P/FRI/23
Diabetes Care Utilization and Glycemic
Control in Young Adults with Type 1
Diabetes Mellitus
C. Sparud Lundin, I. Öhrn, G. Forsander,
E. Danielson
P/FRI/24
Evaluation of Accuracy of Linus,
a new Blood Glucose Meter
C. Maragou, E. Aggelou, K. Zarkogianni,
S. Mougiakakou, D. Delis, L. Stamoyannou,
A. Vazeou
P/FRI/25
Use of Accu-Check Products in Clinical
Practice; Evaluation of Co-Ordinated
Use of Insulin Pump, Glucose Meter
and a Handheld
P. Adolfsson, K. Wiberg, C. Pettersson
P/FRI/26
Glycemic Index and Preprandial
Insulin Affect Postprandial Glucose
Control More than Insulin Type
R. L. Ryan, B. R. King, P. A. Crock,
D. G. Anderson, C. E. Collins, C. E. Smart
P/FRI/27
Amount of Food Group Variety
Consumed by Belgian Diabetic
Children 12 to 18 Years of Age
A. Vanoppen, W. Achten, G. Massa
P/FRI/28
Amount of Fluid Group Variety
Consumed by Belgian Diabetic
Children 6 to 18 Years of Age
W. Achten, A. Vanoppen, G. Massa
P/FRI/29
Children on Intensive Insulin
Therapy Only Need to Count to
10 Gram Carbohydrate Portions
to Maintain Good Glycemic Control
C. Smart, K. Ross, J. Edge, C. Collins, B. King
P/FRI/30
Screening Frequency for Coeliac
Disease in Children with Type 1 Diabetes
Mellitus in a Multicenter Survey
E. E. Froehlich-Reiterer, S. Hofer,
S. Kaspers, A. Herbst, O. Kordonouri,
H. P. Schwarz, E. Schober, M. Grabert,
R. W. Holl, DPV-Wiss Study Group
www.ispad2007.com
Poster Session II
P/FRI/51
National Registers –
Do they Improve Care?
J. Svensson, B. S. Olsen, N. Birkebæk,
F. Pociot, B. Hertz, H. B. Mortensen
P/FRI/52
Incidence of Type 1 Diabetes, MODY
and Type 2 Diabetes in Children Aged
Less than 15 Years and Clinical Characteristics of Type 1 Diabetes at the Time
of Diagnosis: Data from the Childhood
Diabetes Registry in Saxony, Germany
A. Galler, U. Rothe, T. Stange, G. Müller,
R. Koch, A. Näke, C. Vogel, T. Kapellen,
W. Kiess, Childhood Diabetes Registry
in Saxony
P/FRI/53
Incidence of Type 1 Diabetes Mellitus
in Children’s Population in Russian
Federation during 2001-2005 Years
T. Shiryaeva
P/FRI/54
Type 1 Diabetes (T1DM) in Children
and Adolescents of Immigrated
Families in a Region of North Italy
P. Banin, F. Rimondi, A. De Togni, D. Elleri,
B. Predieri, L. Tarchini, G. Chiari, S. Salardi
P/FRI/55
Parental Country of Birth is a Major
Determinant of Childhood Type 1
Diabetes in Sweden
U. W. Söderström, A. Hjern
Syndrome in Children
S. V. Lazebnikova
P/FRI/56
An Impaired Vascular Endothelial
Function is Detectable in Obese
Adolescents
A. Zubkiewicz-Kucharska, A. Noczyńska
The Prevalence of Diabetes
and Impaired Fasting Glucose
in Beijing Schoolchildren
C. Gong
P/FRI/57
Mortality in Patients with ChildhoodOnset Type 1 Diabetes in Norway:
A Population-Based Study
T. Skrivarhaug, L. Sandvik, G. Joner
P/FRI/58
Frequency of DKA in Children
Diagnosed with Type 1 Diabetes in
Montenegro between 1997 and 2006
M. Samardzic, G. Markovic, N. Curovic
Chairs: A. Körner, Budapest; C. Acerini, Cambridge
Chairs: E. Codner, Santiago; W. Lee, Singapore
P/FRI/31
P/FRI/40
P/FRI/32
P/FRI/33
P/FRI/34
P/FRI/35
P/FRI/36
P/FRI/37
Atherosclerotic Changes in Japanese
Patients with Type 1 Diabetes Mellitus
during Adolescence
M. Mochizuki, K. Kobayashi, K. Nagamine,
K. Kobayashi, K. Oyama, S Amemiya
Tumor Necrosis Factor-Alpha
and Interleukin-6 at Early Stage
of Celiac Disease in Type 1 Diabetes
Mellitus Children
M. Myśliwiec, A. Balcerska, K. Zorena,
J. Myśliwska
The Possible Role of Glycemic
Variations to Sleep Disorders in
Children with Insulin Dependent
Diabetes Mellitus – Preliminary Data
A. La Loggia, E. Virone, L. Bivona
Reversible Hepatomegaly due to
Glycogen Storage in Adolescents
with Poorly Controlled Type 1
Diabetes: A Minimalist Form
of the Mauriac Syndrome
D. Dunstheimer, M. Sindichakis,
H. Arnholdt, P. H. Heidemann
Antithrombogenic Activity of
Vessel Wall in Children with
N. Nikolaeva, N. Bolotova, V. Kirichuk,
N. Filina
Endothelial Function in Children
with Type 1 Diabetes Mellitus:
A Longitudinal Study
L. Iughetti, B. Predieri, D. Iaccarino,
S. Madeo, A. L. Quitadamo,
G. Delle Donne, P. Bruzzi, F. Balli,
R. Rossi, M. G. Modena
Early Signs of Left Ventricular
Dysfunction in Adolescents with
Type 1 Diabetes Mellitus: The Importance of Impaired Circadian Modulation of Blood Pressure and Heart Rate
K. Karavanaki, G. Kazianis, E. Tsouvalas,
I. Konstantopoulos, C. Karayianni
Adipo-Insular Interplay at OGTT
in Obese Children
P. Fichna, B. Skowronska, K. Majewska,
W. Stankiewicz
P/FRI/41
Progressive β-Cell Dysfunction in
Obese Children
B. Skowronska, P. Fichna, K. Majewska,
W. Stankiewicz
P/FRI/42
Elevated R-HOMA in Obese Children
and Adolescents with Regard to their
Migration Background
S. Wiegand, A. Dannemann, S. Cherdron,
T. Drossel, K. Raile, A. Grüters
P/FRI/43
P/FRI/44
P/FRI/45
P/FRI/46
P/FRI/47
P/FRI/48
Body Mass Index, Waist Circumference, which is a Better Predictor
of Metabolic Syndrome
B. Cao, C. Gong
Are IVF Children more Prone
to Metabolic Syndrome?
S. Sakka, C. Kanaka-Gantenbein,
A. Malamitsi-Puchner, I. Papasotiriou,
D. Loutradis, G. Chrousos
Prevalence of Impaired Glucose Tolerance and Fasting Hyperinsulinemia
among Obese Adolescents
S. Savva, N. Skordis, C. Chadjigeorgiou,
M. Epiphaniou-Savva, C. Mavromoustakis,
M. Tornaritis, A. Kafatos
Antioxidation Activity and Lipid
Peroxidation in Children with
Insulin Resistance
N. Bolotova, A. P. Averyanov, J. Zotova
Chairs: O. Cinek, Prague; M. Knip, Helsinki
P/FRI/38
P/FRI/39
Homocysteine Levels of Children
with Type 1 Diabetes Mellitus
G. Triantafyllidis, D. Karakaidos, P. Zosi,
M. Vasiliadis, Z. Nikitaki, G. Bozionelos,
C. Karis
Carotid Intima Media Thickness
(cIMT) of Children with Type 1
Diabetes Mellitus
P. Zosi, N. Liasis, G. Triantafyllidis,
M. Vasiliadis, D. Karakaidos, A. Salapata,
C. Karis
www.ispad2007.com
P/FRI/59
Disturbance of Immune Regulatory
Mechanisms in High Risk Relatives
of Type 1 Diabetic Patients
K. Stechova, S. Kolouskova, Z. Hrotekova,
Z. Hladíková, Z. Sumnik, K. Flajsmanova,
Z. Vrabelova, D. Chudoba, M. Pechova,
M. Faresjo, J. Michalek
P/FRI/60
Circulating Nucleic Acids as Inducers
of T Cell Hyperactivity in Juvenile
Diabetes
G. Kocic, L. Saranac, V. Pavlovic, G. Nikolic,
T. Jevtovic, R. Kocic, D. Pavlovic,
G. Bjelakovic
Chairs: T. Urakami, Tokyo; G. Ambler, Sydney
P/FRI/49
Association between Type 1 Diabetes
and Perinatal Factors – Catalonia Study
M. V. Borrás Pérez, A. Freitas, M. Jané,
R. Gispert, C. Castell
P/FRI/50
Common Childhood Vaccinations
and the Risk for Type 1 Diabetes –
an Ecological Study in Germany
J. Rosenbauer, J. B. du Prel, A. Icks,
R. W. Holl, M. Grabert, G. Giani,
in cooperation with ESPED and
the DPV-Wiss Study Group
37
Poster Session II
P/FRI/61
P/FRI/62
P/FRI/63
P/FRI/64
P/FRI/65
P/FRI/66
P/FRI/67
P/FRI/68
Coxsackie B Virus Acts as a Triggering
Environmental Factor in the Pathogenesis of Type 1 Diabetes Mellitus
G. d’Annunzio, A. Giannattasio,
A. Puccetti, C. Bason, C. Lunardi,
V. Morsellino, R. Lorini
No Association between Routinely
Recorded Infections in Early Life
and Subsequent Risk of Childhood
Onset Type 1 Diabetes: A Matched
Case-Control Study Using the UK
General Practice Research Database
C. Cardwell, D. Carson, C. Patterson
Serum Cytokines and Chemokines in
an IgA Deficient Child between Birth
and Development of Celiac Disease
and Type 1 Diabetes
Y. Vainilovich, S. Simell, V. Parikka,
P. Silen, J. Ilonen, M. Knip, T. Simell,
O. Simell
Diabetes and Immunity:
Unusual Presentation of IPEX?
S. Tenoutasse, J. M. Hougardy, F. Mascart,
M. Scaillon, A. Ferster, H. Dorchy
The Non-Inherited Maternal HLA
Haplotype Affects the Risk for
Type 1 Diabetes
K. Åkesson, A. Carlsson, S.-A. Ivarsson,
C. Johansson, J. Ludvigsson, A. Nilsson,
Å. Lernmark, I. Kockum
The Evaluation of Transmission Disequilibrium of Parental Susceptibility
Genes to Patients with ChildhoodOnset Type 1 Diabetes Mellitus (T1DM)
N. Takubo, N. Matsuura, K. Nomoto,
M. Shimohama, S. Otsu, M. Kazahari,
Y. Yokota, M. Ishii
Association of Interleucine
12 P40 (Il-12 P40) Polymorphisms
with Asthma and Diabetes Mellitus
Type 1 (T1DM)
T. Papazoglou, E. Bozas, M. Dokopoulou,
C. Bartsocas, A. Vazeou-Gerasimidi
Association of Alleles at Polymorphic
Sites in the Osteopontin Encoding
Gene in Young Type 1 Diabetic Patients
G. d’Annunzio, R. Marciano,
A. Giannattasio, L. Pasquali, N. Minuto,
A. Santamaria, M. Di Duca, R. Ravazzolo,
R. Lorini
Miscellaneous II
About an Effect of Combined
Therapy of Long-Acting Insulin
(Insulin Glargine) and
Rapid-Acting Insulin Analog
T. Mochizuki
P/FRI/79
Clinical Setting Assessment of
Multiple Daily Injections (MDI)
with Insulin Glargine in 48 Adolescents with Type 1 Diabetes (T1D)
E. Bismuth, C. Delcroix, P. Armoogum,
P. Jacquin, C. Levy-Marchal, C. Alberti,
N. Tubiana Rufi
P/FRI/80
Insulin Glargine Improves Morning
Glycemia and HbA1c in Adolescents
M. Kocova
P/FRI/81
Switching from Glargine to Detemir
can Improve Glycaemic Control and
Reduce Hypoglycaemia in Basal-Bolus
Insulin-Treated Paediatric Patients
with Type 1 Diabetes. 3-Month
Data from a European Cohort
of PREDICTIVE™
J. Bregnhøj, J. Hansen
P/FRI/82
The Rate of Improvement in Metabolic
Control in Children with Diabetes
Mellitus Type 1 on Insulin Glargine
Depends on Age
G. Deja, P. Jarosz-Chobot, J. Polanska
P/FRI/83
Long-Term Improvement of Fasting
Glycemia after Switching Basal
Insulin from NPH to Detemir in
Children with Type 1 Diabetes:
A 1-Year Multicentre Study
Z. Šumník, J. Venháčová, L. Brázdová,
J. Škvor, M. Pecková
P/FRI/84
Higher Insulin Need after Transfer
to Insulin Detemir at Bedtime
Particularly in Younger Children
N. Datz, O. Kordonouri, R. Hartmann,
W. von Schütz, C. Nestoris, T. Danne
P/FRI/85
Lower within-Subject Variability in
Pharmacokinetic Profiles of Insulin
Detemir in Comparison to Insulin
Glargine in Children and Adolescents
T. Danne, L. Endahl, H. Haahr, N. Datz,
C. Nestoris, L. Westergaard, O. Kordonouri
P/FRI/86
Advantages of Treatment
Children Manifesting T1D with
Insulin Analogues
E. Pronina, O. Duchareva, E. Petraikina,
I. Rybkina, T. Mikhailova, E. Mandzhieva
Chairs: D. Becker, Pittsburgh; L. Laffel, Boston
P/FRI/69
Mean Blood Glucose and Biological
Variation have Greater Influence on
HbA1c Levels than Glucose Instability
S. Abourazzak, H. Dorchy, D. Willems,
C. Melot
P/FRI/70
High Glycated Haemoglobin Levels
Influence Injection Pain in Diabetic
H. Dorchy, L. Negoita, M.-P. Roggemans
P/FRI/71
Human Insulin Allergy of Immediate
Type and Insulin-Induced Vasculitis in
a Patient with Diabetes Mellitus Type 1
C. Bartsokas, D. Hatzis
P/FRI/72
The Role of Ghrelin in the Regulation
of Metabolism in Children with IDDMthe Influence of the Kind of Therapy
M. Szalecki, E. Pankowska, E. Piontek,
R. Janas
P/FRI/73
Blood Glucose Profile in Beijing
B. Cao, C. Gong
P/FRI/74
P/FRI/75
P/FRI/76
Studies on the Age-Relation of Insulin
Requirement within the first 10 Days
after Manifestation of Type 1 Diabetes
Mellitus
D. Weitzel, A. Dost, A. Herbst, I. Knerr,
D. Weitzel, W. Hecker, R. Holl, DPV Wiss
Study Group
Ovulatory Function in Adolescents
with Type 1 Diabetes Mellitus
F. Eyzaguirre, G. Iñíguez, P. López, A. Ávila,
I. Torrealba, V. Giadrosich, F. Pérez-Bravo,
F. Cassorla, E. Codner
Short-Term Glucose Concentration
Predictions Based on a Hybrid Model
for Children with Type 1 Diabetes
Using Continuous Glucose
Monitoring Sensor
S. Mougiakakou, A. Prountzou, K. Nikita,
A. Vazeou, C. Bartsocas
Chairs: J. Allgrove, London;
C. Kanaka-Gantenbein, Athens
P/FRI/77
38
P/FRI/78
Experience with Long-Acting
Analogues Insulin on the Pediatric
Diabetes Treatment
M. Ferrer, S. Soto de Ruiz,
G. M. Lou Francés, Z. Galve Pradel,
P. Higueras Sanjuan, M. Rodríguez Rigual
www.ispad2007.com
Poster Session II
Intensified Insulin Treatment, Pumps,
and Sensors III
P/FRI/95
Australian Sensor Augmented Pump
(ASAP) Study
M. A. O’Connell, S. Donath, D. O’Neal,
P. Colman, A. Geoff, T. Jones, E. Davis,
F. Cameron
P/FRI/96
Real Time Insulin Pump (RTIP)
and Continuous Glucose Monitoring
System (CGMS) in Management
of Transient Neonatal Diabetes
Mellitus (TNDM)
R. Padidela, C. Wyatt, D. J. Allgrove
Chairs: D. Deiss, Berlin; F. Cameron, Victoria
P/FRI/87
Can the Introduction of Carbohydrate
Counting Algorithms Integrated
into Pump Therapy Decrease HbA1c
in the Children and Adolescents with
Type 1 Diabetes?
R. Enander, E. Carlzon, J. Chaplin,
U. Dahlström, C. Gundevall,
B. Järelöv-Hjälm, K. Lundqvist, A. Olsson,
E. Printz, A. Strömgren, L. Windell,
R. Hanås
P/FRI/88
Benefits of a Bolus Calculator in
the Glycaemic Control and Meals
Flexibility of Pediatric Patients in
CSII Treatment
N. Sulli, P. Di Stefano, B. Shashaj
P/FRI/89
Evaluation of Postprandial Blood
Glucose Levels Using the Continuous
Glucose Monitoring System (CGMS,
Medtronic) in Type 1 Diabetes Mellitus
Children Treated with Lispro Insulin
in Personal Insulin Pumps
A. Noczyńska, A. Zubkiewicz-Kucharska
P/FRI/90
Improvement of Glycemic Control in
Children with Type 1 Diabetes with
Continuous Glucose Monitoring
Systems (CGMS) and Guardian RT
S. Mougiakakou, K. Zarkogianni,
D. Iliopoulou, A. Chatzoglou, I. Thimelli,
E. Aggelou, C. Maragou, L. Stamoyannou,
A. Vazeou
P/FRI/91
Efficacy of Insulin Detemir in
Children and Adolescents with
Type 1 Diabetes According to
I. Osokina, G. Strelnikov, S. Dmitriev,
D. Osokina
P/FRI/92
in Insulin Pump Treated Children
E. García-García, M.-D. Gámez,
J.-L. Gómez-Llorente, P. Aguilera,
R. Galera, A. Bonillo
P/FRI/93
Continues Glucose Monitoring (SGMS)
in Diabetes Type 1 Children
E. A. Evsyukova, I. G. Kolomina,
G. M. Emelianova, G. F. Okminian,
L. N. Samsonova, E. P. Kasatkina
P/FRI/94
Evaluation of a Real-Time Glucose
Monitoring Influence on Glycemic
Profile in Well Controlled Children
with T1DM
K. Tucholski, E. Skala, G. Deja,
P. Jarosz-Chobot
www.ispad2007.com
39
The Conference Venue
bcc Berliner Congress Center
Timeless modern architecture, spatial configuration and
its central location make the “Berliner Congress Center am
Alexanderplatz” (bcc) a unique event location in Berlin.
From 1961 – 1964 Hermann Henselmann, renowned Bauhausinfluenced architect, created a visionary building complex
with the House of Teachers and the Congress Hall Functionality
and transparency are implemented in futuristic architecture.
The buildings were put under monumental protection in
the 1980s.
40
In 2002 it was converted in a way that preserved the
building’s historic character and yet fundamentally
modernizing the facility. It now offers a significantly
extended and more flexible 10,000 m2 gross floor area
for events since September 2003.
bcc Berliner Congress Center
Alexanderstraße 11
10178 Berlin
www.bcc-berlin.de
www.ispad2007.com
Floor Plans
Level C – First Floor
C01
Main Hall
C02
Exhibition Area
Registration
Level B – Ground Floor
B01 – B02 Exhibition Area
B04
Speakers’ Center
B08 – B09 Poster Exhibition
B05 – B07 Session Room
Main Entrance
Level A – Basement
A01
Meeting Room, Press Conference
A03 – A06 Workshop Rooms
www.ispad2007.com
41
Exhibition Map
Level B
1
2
3
Speakers'
Center
4
5
6
7
Registration
Catering Area
8
11
9
10
13
12
14
15
Cloakroom
16
18
17
19
Entrance
42
Entrance
Exhibitor
Booth
Exhibitor
Booth
Exhibitor
Booth
Abbott Diabetes Care
Animas
Artsana
Bayer HealthCare Diabetes Care
Blackwell Publishing
Diamesco
Eli Lilly & Company
12
15
02
07
03
18
09
Immundiagnostik AG
Integragen
ISPAD
LifeScan
Medtronic
Novo Nordisk
Nova Biomedical
19
05
06
04
08
11
17
Pelikan Technologies
Roche Diagnostics
Terumo
Wisepress
14
10
13
01
Service Areas
Material Display Counter
Booth
16
www.ispad2007.com
Exhibition Map
Level C
20
Catering Area
21
Hospitality
Suite
Catering Area
25
22
Hospitality
Suite
23
Exhibitor
Booth
DAWN Youth
European Society for
Paediatric Endocrinology (ESPE)
International Diabetes
Federation (IDF)
ISPAD 2008 Durban
24
21
www.ispad2007.com
24
Service Areas
Internet Café
sponsored by Novo Nordisk
Booth
22 & 23
20
25
43
tr.
Tors
M
Ale
xa
n
P3
rst
r.
lee
rs
tr.
P2
Rotes
Rathaus
Gr
den
Unter den Lin
Friedrichstr.
Brandeburger
Tor
TXL
Ka
rl-M
arx
-Al
Alexanderplatz
un
e
r
Ka
k
ieb
l-L
Friedrichstraße
c
ne
S
de
U5
U2
U8
r.
-St
ht
P1
U2 Klosterstr.
U8
Alexanderstr.
Hackescher
Markt
oll
str
.
Gr
ei
fs
w
al
de
rS
tr.
Pre
nz
lau
er
U5
Schillingstr.
Jannowitzbrücke
S
THF
Hausvogteiplatz
U2
U2
Stadtmitte
U2 Märkisches
Museum
S
Leipziger Str.
SXF
Reaching the Conference Venue
Berlin can be easily reached from all over Europe as well
as from any destination in the world, thanks to its central
location in Europe and the perfect infrastructure.
Airports
Berlin has three airports: Tegel (TXL), Tempelhof (THF) and
Schönefeld (SXF). All airports have one-stop connections to
Berlin Alexanderplatz.
Berlin is connected to other cities by no less than three
airports, serving about 170 airports in over 50 countries. The
airports of Tegel, Schönefeld and Tempelhof are located in
the north, south and centre of Berlin, allowing transfer times
between 10 and 45 minutes.
An extensive, modern railway and motorway network links
all major cities in Germany and Europe.
Within the city of Berlin, a tightly knitted transport system
with buses, subway and commuter trains allows short
travelling times.
Train
When you arrive in Berlin at the new Berlin Central Station,
just use the commuter train (S-Bahn) to Alexanderplatz – it’s
only three stations away.
Public Transport
Berlin Alexanderplatz (the nearest station to the bcc) can be
reached via:
• Subway: U2, U5, U8
• S-Bahn: S3, S5, S7, S75, S9
• Bus: TXL (Airport), 100, 148, 200, N5, N65, N8
• Tram: M4, M5, M6
Car
There are three car parks in close vicinity to the bcc:
• P1 Alexa-Center
• P2 Rathauspassagen
• P3 Hotel Park Inn Berlin Alexanderplatz
44
www.ispad2007.com
Public Transportation Map
For a detailed public transportation map, please check the
conference website at www.ispad2007.com
www.ispad2007.com
45
Hotel Arcotel Berlin-Mitte * * * *
Oranienburger Straße 52
10117 Berlin
Phone: +49-30-2787-530
Fax: +49-30-2787-53800
Public Transport:
Station: Oranienburger Tor
Subway: U6
Tram: M1
Hotel Courtyard
by Marriott Berlin Mitte * * * *
Axel-Springer-Straße 55
10117 Berlin
Phone: +49-30-8009-280
Fax: +49-30-8009-281000
Public Transport:
Station: Spittelmarkt
Subway: U2
Derag Hotel Königin Luise * * * *
Parkstraße 87
13086 Berlin
Phone +49-30-96247-0
Fax +49-30-96247-160
Hotel Dorint Novotel
Berlin Mitte * * * *
Fischerinsel 12
10179 Berlin
Phone: +49-30-2067-40
Fax : +49-30-2067-4111
Public Transport:
Station: Fischerinsel
Bus: M48, 147 and 248
Station: Märkisches Museum
Subway: U2
Holiday Inn
Berlin City Center East * * * *
Prenzlauer Allee 169
10409 Berlin
Phone: +49-30-44661-0
Fax: +49-30-44661-661
Public Transport:
Station: Prenzlauer Allee
S-Bahn: S8, S41, S42, S85
Tram: M2
Hotel Ibis Berlin-Mitte * * *
Prenzlauer Allee 4
10405 Berlin
Phone: +49-30-4433-30
Fax: +49-30-4433-3111
Public Transport:
Station: Mollstraße / Prenzlauer Allee
Bus: 200
Tram: M2
Station: Prenzlauer Berg
Bus: TXL (Airport)
Station: Rosa-Luxemburg-Platz
Subway: U2
Jolly Hotel Vivaldi * * * *
Friedrichstraße 96
10117 Berlin
Phone: +49-30-2062-660
Fax: +49-30-2062-66999
Public Transport:
Station: Friedrichstraße
S-Bahn: S1, S2, S25, S3, S75, S7, S75, S9
Subway: U6
Bus: 147
Tram: 12, M1
Public Transport:
Station: Albertinenstraße
Tram: M4, M13 and 12
Bus: 255
46
www.ispad2007.com
La Vie Hotel Joachimshof Berlin * * * *
Invalidenstraße 98
10115 Berlin
Phone: +49-30-2039-56100
Fax: +49-30-2039-56199
Public Transport:
Station: Invalidenpark
Bus: 123, 147, 240 and 245
Station: Zinnowitzer Straße
Subway: U6
Tram: M6
Hotel Park Inn
Berlin Alexanderplatz * * * *
Alexanderplatz 7
10178 Berlin
Phone: +49-30-2389-0
Fax: +49-30-2389-4305
Public Transport:
Station: Alexanderplatz
S-Bahn: S3, S75, S7, S75 and S9
Subway: U2, U5 and U8
Bus: TXL (Airport), M48, 100, 200, 248
Tram: M2, M4, M5 and M6
nh Hotel Berlin Alexanderplatz * * * *
Landsberger Allee 26 – 32
10249 Berlin
Phone: +49-30-4226-130
Fax: +49-30-4226-13300
Public Transport:
Station: Platz der Vereinten Nationen
Tram: M5, M6 and M8
Bus: 240
nh Hotel Berlin Mitte * * * *
Leipziger Straße 106 – 111
10117 Berlin
Phone: +49-30-2037-60
Fax: +49-30-2037-6600
Public Transport:
Station: Stadtmitte
Subway: U2, U6
Bus: M48, 347
www.ispad2007.com
Radisson SAS Hotel * * * * *
Karl-Liebknecht-Straße 3
10178 Berlin
Phone: +49-30-23828-0
Fax: +49-30-23828-10
Public Transport:
Station: Hackescher Markt
S-Bahn: S3, S75, S7, S75 and S9
Station: Spandauer Straße/ Marienkirche
Bus: 100, 200
Ramada Hotel Berlin Mitte * * * *
Chausseestraße 118
10115 Berlin
Phone: +49-30-2787-550
Fax: +49-30-2787-55550
Public Transport:
Station: Oranienburger Tor
Subway: U6
Hotel Upstalsboom Berlin * * * *
Gubener Straße 42
(Entrance Kopernikusstraße 36)
10243 Berlin
Phone: +49-30-2937-50
Fax: +49-30-2937-5777
Public Transport:
Station: Weberwiese/ Frankfurter Tor
Subway: U5
Station: Gubener Straße
Bus: 347
Westin Grand Hotel Deluxe * * * * *
Friedrichstraße 158-164
10117 Berlin
Phone: +49-30-2027-0
Fax: +49-30-2027-3362
Public Transport:
Station: Französische Straße
Subway: U6
Station: Friedrichstraße
S-Bahn: S1, S2, S25, S3, S75, S7, S75, S9
47
The City of Berlin
The City of Berlin
Berlin, Capital of the Federal Republic of Germany, is located
at the heart of Europe and also, after the EU enlargement in
2004, at the centre of the European Community. With about
3,400,000 inhabitants, Berlin is the largest city in Germany.
In recent years, Berlin has established itself as one of the most
attractive destinations for trade fairs, conventions, meetings
and incentives. But Berlin is far more than just a meeting point
for leading people from science, business and politics. Unique
cultural and recreational attractions are waiting to be discovered in Berlin.
You may wish to visit one of the 3 excellent opera houses,
experience a performance at one of Berlin’s 150 diverse
theaters, or attend a Berlin philharmonic concert conducted
by Sir Simon Rattle in the unconventional and world famous
Berlin Philharmonic Hall. Berlin’s extensive multi-sided cultural
programs fulfill even the most sophisticated expectations.
Treasures of world heritage, such as the Pergamon Altar or
the bust of Queen Nofretete, are just two examples of the
prized artefacts that can be viewed in Berlin’s more than
160 museums and 350 galleries.
You can also experience the impressive architectural richness
of Berlin. Tour famous constructions by viewing examples
of former East German architecture at Alexanderplatz and
continue down the magnificent Unter den Linden Boulevard
with its many 19th Century constructions by Karl Friedrich
Schinkel. Step through Brandenburg Gate and visit the internationally renowned glass dome atop the German Parliament
building, designed by the architect Sir Norman Foster. Potsdamer Platz, the apparent playground of modern architects,
attracts visitors not only with its futuristic glass and steel
constructions, such as the Sony Center designed by Helmut
Jahn, but also with its shopping mall, cinemas, restaurants
and cafés.
For a more relaxed afternoon, enjoy a leisurely stroll through
the Tiergarten, the largest nature preserve in Berlin, or enjoy
a refreshing drink at one of the lively German beer gardens.
And do not forget to visit Potsdam, with the famous
Sanssouci Palace, the beautiful park and the historical
Cecilienhof Memorial.
Berlin is waiting for you.
48
www.ispad2007.com
Berlin City & Hotel Map
For a detailed berlin city & hotel map, please check the
conference website at www.ispad2007.com
www.ispad2007.com
49
Social Program
Opening Ceremony and
Welcome Reception at the bcc
Social Afternoon
September 26, 2007, Room C01, 18.30 – 20.30
Boat trip & garden party at the “Haus der Kulturen der Welt”
Following the official Opening Ceremony, ISPAD invites all
delegates to the Welcome Reception to be held at the bcc. The
reception will be filled with multicultural entertainment and
children celebrating the festival of carnival. Be part of the festival
and enjoy an evening of the special kind – a perfect opportunity
to meet old friends, refresh contacts and start new networks.
The social afternoon will begin with a boat trip embarking
from the landing dock “Märkisches Ufer” cruising the Spree
River. Along with coffee, tea and cake you will enjoy some of the
most important places of interest within the city from a very
unusual perspective. Ending at the newly renovated “Haus der
Kulturen der Welt”, a remarkable landmark in the cityscape of
post-war Berlin, which is and has been for 50 years, a centre for
contemporary arts and a venue for projects breaking through
artistic boundaries. There, in the middle of the green lung of
Berlin, the Tiergarten, you will experience German hospitality
in a casual atmosphere at a typical Berlin garden party. Hot
sausages, cold Berliner Weisse and music entertainment should
not be missed when in Berlin!
This evening is free of charge to all registered delegates,
accompanying persons and industry representatives.
P
50
www.ispad2007.com
Social Program
Society’s Evening
Departure
15.15 guided walk from bcc (outside main entrance) to landing
dock “Märkisches Ufer”
15.45 departure from landing dock “Märkisches Ufer” (cruise
company “Stern und Kreis Schiffahrt GmbH”)
The evening will start with the reception in the atrium of the
representation of the German Telekom in Berlin. A seated dinner
will cater for your well-being followed by an opulent dessert
buffet. Afterwards, the ISPAD Prizes will be awarded to the prize
winners. Come along and dance the night away!
Address
Hauptstadtrepräsentanz der Deutschen Telekom
Französische Str. 33 a – c, 10117 Berlin
Transfer
Public Transportation to landing dock “Märkisches Ufer”
by S-Bahn: train station “Jannowitzbrücke”, S-Bahn No. S3, S5, S7, S75
by U-Bahn: metro station “Märkisches Museum” No. U2
or metro station “Jannowitzbrücke” No. U8
A bus transfer is available:
Route 1: Departure at 19.00 at Jolly Vivaldi Hotel (on the corner
of Planck Str. and Georgen Str.) via Westin Grand Hotel (entrance
Behrenstr.) at 19.10.
Route 2: Departure at 19.00 at Park Inn Hotel via bcc at 19.10
Limited capacity.
Return Transfer
A shuttle service will run between 20.30 and 23.00 via Westin
Grand Hotel, the bcc and Hotel Park Inn Berlin Alexanderplatz.
Limited capacity.
Public Transportation from “Haus der Kulturen der Welt”
by bus: bus stop “Haus der Kulturen der Welt” /
John – Foster – Dulles – Allee, Bus No.: 100
Return Transfer
A shuttle service will run between 22.30 and 00.30 via Westin
Grand Hotel, Jolly Vivaldi Hotel, the bcc and Hotel Park Inn Berlin
Alexanderplatz. Limited capacity.
Public Transportation (to / from) by Subway (U-Bahn):
Train station “Hausvogteiplatz” / Subway: U2
Train station “Französische Str.” / Subway: U6
Dress Code
Elegant Casual
www.ispad2007.com
51
Tours
Tours
All tours depart and end at the bcc
1. The Berlin Orientation Tour
Berlin has always been a dynamic city, noted for its ambitious
and vivacious nature. The Berlin Orientation Tour gives a
general overview of the signs of change throughout the city
and of its most traditional and popular highlights. The bus
tour includes sights like the Brandenburg Gate, the German
House of Parliament and the Victory Column as well as the
Emperor Wilhelm’s Memorial Church, the Berlin Cathedral
and Charlottenburg Palace. Furthermore, the bus will pass
the futuristic Potsdamer Platz with the Philharmonic Concert
Hall and the Alexanderplatz with the Red Town Hall, the
official Lord Mayor’s residence.
Wednesday, September 26, 2007 ...................................10.00 – 13.00
€ 25 p.p.
2. The Government Quarter
The tour focuses on the government buildings of the Capital,
most of which have been built or renovated after the fall of
the Berlin Wall. It begins at the most famous location in Berlin, the Pariser Platz where the French, the English and the
American embassies all surround the Brandenburg Gate.
On the other side of the Brandenburg Gate, towards the Spree
River and just in front of the new ministries, we will make a
stop at the Reichstag. After a complete renovation under the
direction of Sir Norman Foster, the “new” Reichstag with its
glass dome gives visitors an amazing view over Berlin and
has become a symbol of German unity.
52
Our tour will continue in the West of the city. Next stop, just
in front of the Reichstag, is the new Chancellery. Passing
through the Tiergarten, you will see the Schloss Bellevue,
residence of the German President.
Wednesday, September 26, 2007 ....................................13.00 – 16.30
€ 27 p.p.
3. Berlin Underground
This tour shows you the city from a very original and
unknown perspective: the underground of Berlin. Not only
the common facilities such as the subway and the drainage
system are part of Berlin’s Underground but also Berlin’s late
19th Century pneumatic pipe post system as well as an extensive bunker system. All of these elements played a part in the
dramatic history of the German Capital in the 20th Century
through WWII and the Cold War.
This tour also shows how deep the impact of the Cold War
and the Division of Berlin (1961–1989) in the Underground
world has been: you will pass through the “nuclear blast-proof”
bunker beneath Blochplatz, its white-washed walls, large
metal doors and modern ventilation systems and enjoy an
exhibition of the finds that the Berliner Underworld
Association have retrieved during their work below ground.
Thursday, September 27, 2007 ........................................ 10.00 – 12.30
€ 33 p.p.
www.ispad2007.com
Tours
4. Jewish History in Berlin
The tour focuses on the Jewish history in Berlin. After a visit
to the spectacular Jewish Museum, participants will then
continue the tour in the so-called “Scheunenviertel” where
the Jewish community used to live before the war. Lastly we
will have a look at the huge memorial for the victims of the
holocaust situated in close proximity to the
Brandenburg Gate.
Friday, September 28, 2007 .............................................09.00 – 13.00
€ 38 p.p.
5. A journey through Berlin’s architecture
The reunified city of Berlin offers a kaleidoscope of all most
important trends in the history of architecture: from NeoClassical to Post Modern, from Neo-Gothic to Bauhaus, from
Socialist to the American 50’s without forgetting the German
Art Nouveau. This tour will show you some of the best
examples of all these sources of inspiration: Alexanderplatz,
Gendarmenmarkt, Unter den Linden, Karl-Marx Allee and
of course what we commonly call now the “New Berlin”
designed since the Fall of the Wall by world famous architects
like Leoh Ming Pei, Jean Nouvel, Daniel Libeskind, Frank O.
Gehry, Renzo Piano and many others.
Saturday, September 29, 2007 ....................................... 09.30 – 13.00
€ 30 p.p.
www.ispad2007.com
6. Full-Day Tour to Potsdam
The capital of the Land of Brandenburg, Potsdam is located
in a beautiful hill area between vast waterways of the Havel
and numerous lakes. In 1660, the Brandenburg Elector,
Friedrich Wilhelm, chose Potsdam to be his place of residence.
Frederick the Great and others strongly influenced the city
and its architecture. The tour of the old town will include
the following sights: The Brandenburg Gate at Potsdam, the
Dutch Quarter, the Marstall and the Nikolai Church.
After that, the tour continues to the Garden of Sanssouci,
including the Palace Sanssouci, the New Palace, the Orangerie,
the New Chambers, as well as the Chinese Tea House and the
Dutch Windmill.
After the visit of Sanssouci Park, we will go to the New Garden
to have lunch (included) in the Castle of Cecilienhof, the place
where, in 1945, the Potsdam Conference with Stalin, Churchill
and Truman, took place.
Friday, September 28, 2007 .............................................09.00 – 17.00
€ 95 p.p.
Also, if you are interested in sports, you may want to attend
the 34th Berlin Marathon which takes place on September 30,
2007. The 34th Berlin Marathon will boost a field of more than
40,000 athletes from over 100 nations.
Check www.berlin-marathon.de for details. Please note that
neither ISPAD nor K.I.T. GmbH & Co. KG are responsible in any
way for this event.
53
ISPAD
International Society for Pediatric
and Adolescent Diabetes
Conference Secretariat
c/o K.I.T. GmbH Association & Conference Management Group & Co. KG
Kurfürstendamm 71, 10709 Berlin, Germany
Fax: +49-30-24603-200
One copy of this form should be completed for each applicant. Please type or print clearly in capitals.
Personal Information (all fields are mandatory)
ò Mr
ò Mrs
ò Ms
ò Dr
Last name
First name
Company / Institution
Department
Street / P.O. Box
ZIP Code
Country
ò Prof
Birthday
City
Phone
Fax
Email
Institution´s Website
Scientific Information
Main research topics
Profession
ò Doctor
ò Dietitian
ò Nurse
ò
Please indicate two current members of ISPAD who can endorse your application.
1. Name
Email
2. Name
Email
Membership requirements include completing this application plus a brief CV summarizing your current work and interest in pediatric and adolescent
diabetes. Please attach the CV to this application. Annual Fees are 100 USD (including subscription of Pediatric Diabetes) payable by credit card only.
Herewith I authorize the ISPAD Secretariat, K.I.T. GmbH & Co. KG, to charge my credit card with the amount of 100.00 USD, to become a member of ISPAD.
ò Visa
ò Mastercard
Credit Card No
Expiry date
Card Verification Code (last three digits on reverse side of the card)
54
Cardholder
Signature
Date, Place
Signature
www.ispad2007.com
Bayer, the Bayer cross, CONTOUR, CONTOUR TS, CONTOUR LINK and the NO CODING logo are trademarks of Bayer.
MiniMed Paradigm and Guardian REAL-Time System are registered trademarks of Medtronic.
.OTES2EMINDERS
$OYOURPATIENTSCODETHEIR
BLOODGLUCOSEMETERS
Always
What is Coding?
Most of the Time
Yes
See how easy pediatric dosing can be
Introducing high
performance blood
glucose meters
.O#ODINGTECHNOLOGY FROM"AYERELIMINATES
MISCODINGERRORSAND
ASSOCIATEDCLINICALRISKS
!CCURACYFORRELIABLE
RESULTS
Final Program | 33rd Annual Meeting | International Society for Pediatric and Adolescent Diabetes
s
s
Introducing HumaPen® LUXURATM HD
HumaPen LUXURA HD gives parents and caregivers
of children with diabetes precise dosing of Humalog®
in half-unit increments from 1 to 30 units.
• Accurate
• Precise
• Convenient
Seeing is believing.
Visit the Lilly booth for a demonstration.
For complete instructions on HumaPen LUXURA HD, please reference the full user manual provided with the Pen.
HUMALOG* VIAL, CARTRIDGE, AND PEN (100U/ML) ABBREVIATED PRESCRIBING INFORMATION
HUMALOG IS INSULIN LISPRO (HUMAN INSULIN ANALOGUE)
Presentation: Humalog is a sterile, clear, colourless, aqueous solution of insulin lispro
([Lys (B28), Pro (B29)] human insulin analogue of recombinant DNA origin).
Uses: Treatment of diabetes mellitus.
Dosage and Administration: The dosage should be determined by the physician, according to the requirement of the
patient. Humalog may be given shortly before meals and, when necessary, can be given soon after meals. Humalog can be
given in conjunction with a longer acting human insulin. Humalog should be given by subcutaneous injection or by
continuous subcutaneous infusion pump, and may, although not recommended, also be given by intramuscular injection. If
necessary, Humalog may also be administered intravenously, for example, for the control of blood glucose levels during
ketoacidosis, acute illness, or perioperatively. Humalog cartridges are to be used with a CE marked pen. Follow the pen
manufacturer’s directions for loading the pen and priming it. Patients should be advised to always keep a spare pen and/or
cartridge. Humalog takes effect rapidly (approximately 15 minutes). See Summary of Product Characteristics for additional
information, including time-action profiles.
Contra-indications: Hypersensitivity to insulin lispro or to any of the excipients. Hypoglycaemia.
#/.4/52®,INKWIRELESSLYTRANSMITSBLOOD
GLUCOSERESULTSTOCOMPATIBLE-INI-ED
0ARADIGM®)NSULIN0UMPSANDTHE'UARDIAN®
2%!,4IME3YSTEM
Easy Accuracy. Answered by Bayer.
www.bayerdiabetes.com
Warnings and Special Precautions: Transferring to another type or brand of insulin should be done under strict medical
supervision. Changes in strength, brand, type, species, and/or method of manufacture may result in the need for a change
in dosage. For fast-acting insulins, any patient also on basal insulin must optimise dosage of both insulins to obtain
glucose control across the whole day, particularly nocturnal/fasting glucose control. Changes in early warning symptoms of
hypoglycaemia may occur on transfer between different types of insulin products. Insulin requirements may be reduced in
the presence of renal impairment or hepatic impairment. However, in patients with chronic hepatic impairment, an increase
in insulin resistance may lead to increased insulin requirements. Insulin requirements may be increased during illness or
emotional disturbances. Insulin lispro should be used in children only when an advantage is expected compared to soluble
insulin, for example, in the timing of the injection in relation to meals. The patient’s ability to concentrate and react may be
PM141377
impaired as a result of hypoglycaemia. This may constitute a risk in situations where these abilities are of special
importance (eg, driving a car or operating machinery). Usage in pregnancy: Data on a large number of exposed pregnancies
do not indicate any adverse effect of insulin lispro on pregnancy or on the health of the foetus/newborn. Insulin requirements
usually fall during the first trimester and increase during the second and third trimesters. Patients should be advised to
inform their doctors if they are pregnant or contemplating pregnancy.
Undesirable Effects: Hypoglycaemia is the most frequent undesirable effect of insulin therapy.
Local allergy is common and usually resolves. Systemic allergy is rare but potentially more serious since severe cases may
be life-threatening. Lipodystrophy is uncommon.
For full details of side-effects please consult the Summary of Product Characteristics, which is available at
http://emc.medicines.org.uk
Legal Category: POM
Prices: £17.28 - 1 x 10ml vials.
£29.46 - 5 x 3ml cartridges.
£29.46 - 5 x 3ml Humalog-Pens.
Marketing Authorisation Numbers:
Humalog vial: EU/1/96/007/002
Humalog cartridge: EU/1/96/007/004
Humalog-Pen 3ml: EU/1/96/007/015
Date of Preparation or Last Review: April 2007
Full Prescribing Information is Available From: Eli Lilly and Company Limited,
Lilly House, Priestley Road, Basingstoke, Hampshire, RG24 9NL
Telephone: Basingstoke (01256) 315 999
*HUMALOG (insulin lispro) is a trademark of Eli Lilly and Company
LP496 April 2007

Final Program

Transcription

Similar documents

Education

ARC factsheet Special Research Initiative for Type 1 Juvenile

Tim McGraw has a challenge for you.

NIDDK Medical Student Research Program in Diabetes and Obesity

Diabetes, Type 1

Living with diabetes

RegEnergetik –

Summary of University of Surrey Academic F2 projects 2012-15

By Quisa Foster - Cascade United Methodist Church

outside page - Pure Jeevan